Target Gene/Pathway Pathway / Gene

  

Search results

No. KEGG GENES KEGG PATHWAY KEGG DRUG DrugBank 指定難病告示番号
1 SIGMAR1 2件: Amyotrophic lateral sclerosis, Pathways of neurodegeneration - multiple diseases D00848 Dextromethorphan 11件: 2, 6, 8, 13, 21, 46, 78, 85, 96, 97, 156
2 SIGMAR1 2件: Amyotrophic lateral sclerosis, Pathways of neurodegeneration - multiple diseases D03742 Dextromethorphan 11件: 2, 6, 8, 13, 21, 46, 78, 85, 96, 97, 156
3 SIGMAR1 2件: Amyotrophic lateral sclerosis, Pathways of neurodegeneration - multiple diseases D03744 Dextromethorphan 11件: 2, 6, 8, 13, 21, 46, 78, 85, 96, 97, 156
4 TUBB3 10件: Phagosome, Gap junction, Alzheimer disease, Parkinson disease, Amyotrophic lateral sclerosis, Huntington disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Salmonella infection D00491 Paclitaxel 2件: 46, 85
5 TUBB3 10件: Phagosome, Gap junction, Alzheimer disease, Parkinson disease, Amyotrophic lateral sclerosis, Huntington disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Salmonella infection D00570 Colchicine 7件: 2, 42, 46, 56, 93, 210, 266
6 TUBB3 10件: Phagosome, Gap junction, Alzheimer disease, Parkinson disease, Amyotrophic lateral sclerosis, Huntington disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Salmonella infection D05333 Paclitaxel 2件: 46, 85
7 TUBB4A 10件: Phagosome, Gap junction, Alzheimer disease, Parkinson disease, Amyotrophic lateral sclerosis, Huntington disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Salmonella infection D00491 Paclitaxel 2件: 46, 85
8 TUBB4A 10件: Phagosome, Gap junction, Alzheimer disease, Parkinson disease, Amyotrophic lateral sclerosis, Huntington disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Salmonella infection D00570 Colchicine 7件: 2, 42, 46, 56, 93, 210, 266
9 TUBB4A 10件: Phagosome, Gap junction, Alzheimer disease, Parkinson disease, Amyotrophic lateral sclerosis, Huntington disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Salmonella infection D05333 Paclitaxel 2件: 46, 85
10 TUBB4B 10件: Phagosome, Gap junction, Alzheimer disease, Parkinson disease, Amyotrophic lateral sclerosis, Huntington disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Salmonella infection D00491 Paclitaxel 2件: 46, 85
11 TUBB4B 10件: Phagosome, Gap junction, Alzheimer disease, Parkinson disease, Amyotrophic lateral sclerosis, Huntington disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Salmonella infection D00570 Colchicine 7件: 2, 42, 46, 56, 93, 210, 266
12 TUBB4B 10件: Phagosome, Gap junction, Alzheimer disease, Parkinson disease, Amyotrophic lateral sclerosis, Huntington disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Salmonella infection D05333 Paclitaxel 2件: 46, 85
13 CD52 - D02802 Alemtuzumab 15件: 46, 49, 51, 60, 62, 63, 65, 85, 96, 164, 234, 283, 284, 285, 326
14 TNFSF13B 4件: Cytokine-cytokine receptor interaction, NF-kappa B signaling pathway, Intestinal immune network for IgA production, Rheumatoid arthritis D03068 Belimumab 12件: 11, 13, 43, 44, 46, 49, 51, 53, 66, 222, 296, 300
15 TNFSF13B 4件: Cytokine-cytokine receptor interaction, NF-kappa B signaling pathway, Intestinal immune network for IgA production, Rheumatoid arthritis D09704 Atacicept 4件: 13, 46, 49, 66
16 TNFSF13B 4件: Cytokine-cytokine receptor interaction, NF-kappa B signaling pathway, Intestinal immune network for IgA production, Rheumatoid arthritis D10083 Tabalumab 2件: 46, 49
17 TNFSF13B 1件: Rheumatoid arthritis D11127 Tibulizumab 1件: 53
18 CYSLTR1 2件: Calcium signaling pathway, Neuroactive ligand-receptor interaction D00529 Montelukast 8件: 6, 13, 46, 61, 63, 85, 98, 228
19 CYSLTR1 2件: Calcium signaling pathway, Neuroactive ligand-receptor interaction D08229 Montelukast 8件: 6, 13, 46, 61, 63, 85, 98, 228
20 IL17F 4件: Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Th17 cell differentiation, Inflammatory bowel disease D11550 Bimekizumab 3件: 46, 97, 271
21 TNFRSF13C 5件: Cytokine-cytokine receptor interaction, NF-kappa B signaling pathway, Intestinal immune network for IgA production, Human T-cell leukemia virus 1 infection, Primary immunodeficiency D12151 Ianalumab 5件: 35, 46, 49, 53, 95
22 CCR5 9件: Cytokine-cytokine receptor interaction, Viral protein interaction with cytokine and cytokine receptor, Chemokine signaling pathway, Endocytosis, Toxoplasmosis, Human cytomegalovirus infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, Viral carcinogenesis D06670 Maraviroc 2件: 46, 84
23 CNR1 4件: Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Thermogenesis, Retrograde endocannabinoid signaling D00306 Dronabinol 8件: 2, 8, 13, 36, 46, 96, 271, 298
24 CNR1 4件: Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Thermogenesis, Retrograde endocannabinoid signaling D10915 Cannabidiol 19件: 2, 6, 8, 13, 36, 46, 95, 96, 97, 140, 144, 145, 156, 157, 158, 193, 206, 226, 271
25 CNR2 1件: Neuroactive ligand-receptor interaction D00306 Dronabinol 4件: 46, 96, 271, 298
26 CNR2 1件: Neuroactive ligand-receptor interaction D10915 Cannabidiol 14件: 46, 95, 96, 97, 140, 144, 145, 156, 157, 158, 193, 206, 226, 271
27 ADORA1 7件: cGMP-PKG signaling pathway, cAMP signaling pathway, Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Morphine addiction D00528 Caffeine 9件: 2, 6, 13, 21, 46, 78, 96, 97, 265
28 ADORA1 7件: cGMP-PKG signaling pathway, cAMP signaling pathway, Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Morphine addiction D01453 Caffeine 9件: 2, 6, 13, 21, 46, 78, 96, 97, 265
29 ADORA1 7件: cGMP-PKG signaling pathway, cAMP signaling pathway, Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Morphine addiction D02769 Adenosine phosphate 1件: 46
30 ADORA2A 7件: Rap1 signaling pathway, Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Parkinson disease, Alcoholism D00528 Caffeine 9件: 2, 6, 13, 21, 46, 78, 96, 97, 265
31 ADORA2A 7件: Rap1 signaling pathway, Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Parkinson disease, Alcoholism D01453 Caffeine 9件: 2, 6, 13, 21, 46, 78, 96, 97, 265
32 ADORA2A 7件: Rap1 signaling pathway, Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Parkinson disease, Alcoholism D02769 Adenosine phosphate 1件: 46
33 ADORA2B 5件: Rap1 signaling pathway, Calcium signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Alcoholism D02769 Adenosine phosphate 1件: 46
34 ADORA3 3件: cGMP-PKG signaling pathway, Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction D02769 Adenosine phosphate 1件: 46
35 ADORA3 3件: cGMP-PKG signaling pathway, Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction D10971 Piclidenoson 1件: 46
36 CSF1 3件: Viral protein interaction with cytokine and cytokine receptor, TNF signaling pathway, Rheumatoid arthritis D06402 Sunitinib 2件: 28, 34
37 CSF1 3件: Viral protein interaction with cytokine and cytokine receptor, TNF signaling pathway, Rheumatoid arthritis D08552 Sunitinib 2件: 28, 34
38 CSF2 16件: Cytokine-cytokine receptor interaction, JAK-STAT signaling pathway, Hematopoietic cell lineage, Natural killer cell mediated cytotoxicity, IL-17 signaling pathway, T cell receptor signaling pathway, Fc epsilon RI signaling pathway, TNF signaling pathway, Shigellosis, Amoebiasis, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Coronavirus disease - COVID-19, Transcriptional misregulation in cancer, Acute myeloid leukemia, Rheumatoid arthritis D11343 Otilimab 2件: 46, 256
39 CSF2RA 4件: Cytokine-cytokine receptor interaction, JAK-STAT signaling pathway, Hematopoietic cell lineage, Pathways in cancer D09930 Mavrilimumab 2件: 41, 46
40 CSF3R 5件: Cytokine-cytokine receptor interaction, PI3K-Akt signaling pathway, JAK-STAT signaling pathway, Hematopoietic cell lineage, Pathways in cancer D03235 Filgrastim 34件: 2, 6, 11, 13, 16, 25, 26, 28, 34, 35, 36, 38, 40, 41, 42, 45, 46, 47, 49, 51, 57, 60, 62, 65, 85, 96, 113, 164, 256, 283, 284, 285, 296, 331
41 ADRA1D 6件: Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion D00095 Epinephrine 3件: 46, 70, 96
42 ADRA1D 6件: Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion D00996 Epinephrine 3件: 46, 70, 96
43 ADRA1D 6件: Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion D02149 Epinephrine 3件: 46, 70, 96
44 ADRA1B 6件: Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion D00095 Epinephrine 3件: 46, 70, 96
45 ADRA1B 6件: Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion D00996 Epinephrine 3件: 46, 70, 96
46 ADRA1B 6件: Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion D02149 Epinephrine 3件: 46, 70, 96
47 ADRA1A 7件: Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, AMPK signaling pathway, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion D00095 Epinephrine 3件: 46, 70, 96
48 ADRA1A 7件: Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, AMPK signaling pathway, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion D00996 Epinephrine 3件: 46, 70, 96
49 ADRA1A 7件: Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, AMPK signaling pathway, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion D02149 Epinephrine 3件: 46, 70, 96
50 CTLA4 2件: T cell receptor signaling pathway, Rheumatoid arthritis D04603 Ipilimumab 1件: 159
51 CTLA4 2件: T cell receptor signaling pathway, Rheumatoid arthritis D06657 Tremelimumab 1件: 96
52 ADRA2A 2件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D00095 Epinephrine 3件: 46, 70, 96
53 ADRA2A 2件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D00514 Dexmedetomidine 13件: 2, 4, 6, 21, 34, 46, 70, 107, 113, 212, 215, 226, 280
54 ADRA2A 2件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D00996 Epinephrine 3件: 46, 70, 96
55 ADRA2A 2件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D01205 Dexmedetomidine 13件: 2, 4, 6, 21, 34, 46, 70, 107, 113, 212, 215, 226, 280
56 ADRA2A 2件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D02149 Epinephrine 3件: 46, 70, 96
57 ADRA2B 2件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D00095 Epinephrine 3件: 46, 70, 96
58 ADRA2B 2件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D00514 Dexmedetomidine 13件: 2, 4, 6, 21, 34, 46, 70, 107, 113, 212, 215, 226, 280
59 ADRA2B 2件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D00996 Epinephrine 3件: 46, 70, 96
60 ADRA2B 2件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D01205 Dexmedetomidine 13件: 2, 4, 6, 21, 34, 46, 70, 107, 113, 212, 215, 226, 280
61 ADRA2B 2件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D02149 Epinephrine 3件: 46, 70, 96
62 ADRA2C 2件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D00095 Epinephrine 3件: 46, 70, 96
63 ADRA2C 2件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D00514 Dexmedetomidine 13件: 2, 4, 6, 21, 34, 46, 70, 107, 113, 212, 215, 226, 280
64 ADRA2C 2件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D00996 Epinephrine 3件: 46, 70, 96
65 ADRA2C 2件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D01205 Dexmedetomidine 13件: 2, 4, 6, 21, 34, 46, 70, 107, 113, 212, 215, 226, 280
66 ADRA2C 2件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D02149 Epinephrine 3件: 46, 70, 96
67 ADRB1 11件: Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Gap junction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy D00095 Epinephrine 3件: 46, 70, 96
68 ADRB1 11件: Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Gap junction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy D00996 Epinephrine 3件: 46, 70, 96
69 ADRB1 11件: Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Gap junction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy D02149 Epinephrine 3件: 46, 70, 96
70 ADRB2 9件: Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation D00095 Epinephrine 3件: 46, 70, 96
71 ADRB2 9件: Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation D00996 Epinephrine 3件: 46, 70, 96
72 ADRB2 9件: Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation D02149 Epinephrine 3件: 46, 70, 96
73 ADRB3 8件: Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Thermogenesis, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation D00095 Epinephrine 3件: 46, 70, 96
74 ADRB3 8件: Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Thermogenesis, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation D00996 Epinephrine 3件: 46, 70, 96
75 ADRB3 8件: Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Thermogenesis, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation D02149 Epinephrine 3件: 46, 70, 96
76 ACE 6件: Renin-angiotensin system, Renin secretion, Chagas disease, Coronavirus disease - COVID-19, Hypertrophic cardiomyopathy, Diabetic cardiomyopathy D00251 Captopril 8件: 6, 17, 46, 86, 96, 97, 107, 271
77 ACE 6件: Renin-angiotensin system, Renin secretion, Chagas disease, Coronavirus disease - COVID-19, Hypertrophic cardiomyopathy, Diabetic cardiomyopathy D00362 Lisinopril 7件: 19, 46, 49, 66, 67, 113, 222
78 ACE 6件: Renin-angiotensin system, Renin secretion, Chagas disease, Coronavirus disease - COVID-19, Hypertrophic cardiomyopathy, Diabetic cardiomyopathy D00421 Ramipril 7件: 46, 49, 66, 67, 113, 218, 257
79 ACE 6件: Renin-angiotensin system, Renin secretion, Chagas disease, Coronavirus disease - COVID-19, Hypertrophic cardiomyopathy, Diabetic cardiomyopathy D00621 Enalapril 6件: 19, 46, 66, 113, 210, 222
80 ACE 6件: Renin-angiotensin system, Renin secretion, Chagas disease, Coronavirus disease - COVID-19, Hypertrophic cardiomyopathy, Diabetic cardiomyopathy D07892 Enalapril 6件: 19, 46, 66, 113, 210, 222
81 ACE 6件: Renin-angiotensin system, Renin secretion, Chagas disease, Coronavirus disease - COVID-19, Hypertrophic cardiomyopathy, Diabetic cardiomyopathy D08131 Lisinopril 7件: 19, 46, 49, 66, 67, 113, 222
82 DHFR 5件: One carbon pool by folate, Folate biosynthesis, Metabolic pathways, Biosynthesis of cofactors, Antifolate resistance D00142 Methotrexate 38件: 11, 13, 19, 34, 35, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 53, 55, 56, 60, 62, 65, 84, 93, 96, 97, 107, 162, 164, 172, 256, 270, 271, 283, 284, 285, 286, 326, 331
83 DHFR 5件: One carbon pool by folate, Folate biosynthesis, Metabolic pathways, Biosynthesis of cofactors, Antifolate resistance D02115 Methotrexate 38件: 11, 13, 19, 34, 35, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 53, 55, 56, 60, 62, 65, 84, 93, 96, 97, 107, 162, 164, 172, 256, 270, 271, 283, 284, 285, 286, 326, 331
84 DHODH 3件: Pyrimidine metabolism, Metabolic pathways, Biosynthesis of cofactors D00749 Leflunomide 12件: 11, 40, 46, 49, 53, 66, 107, 162, 224, 270, 271, 300
85 NQO1 7件: Ubiquinone and other terpenoid-quinone biosynthesis, Metabolic pathways, Biosynthesis of cofactors, Pathways in cancer, Chemical carcinogenesis - reactive oxygen species, Hepatocellular carcinoma, Fluid shear stress and atherosclerosis D00564 Warfarin 13件: 6, 8, 13, 19, 46, 49, 66, 85, 86, 88, 91, 96, 97
86 NQO1 7件: Ubiquinone and other terpenoid-quinone biosynthesis, Metabolic pathways, Biosynthesis of cofactors, Pathways in cancer, Chemical carcinogenesis - reactive oxygen species, Hepatocellular carcinoma, Fluid shear stress and atherosclerosis D01280 Warfarin 13件: 6, 8, 13, 19, 46, 49, 66, 85, 86, 88, 91, 96, 97
87 NQO1 7件: Ubiquinone and other terpenoid-quinone biosynthesis, Metabolic pathways, Biosynthesis of cofactors, Pathways in cancer, Chemical carcinogenesis - reactive oxygen species, Hepatocellular carcinoma, Fluid shear stress and atherosclerosis D08682 Warfarin 13件: 6, 8, 13, 19, 46, 49, 66, 85, 86, 88, 91, 96, 97
88 DRD2 8件: Rap1 signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease, Cocaine addiction, Alcoholism D01226 Sulpiride 5件: 2, 6, 17, 46, 70
89 DRD2 8件: Rap1 signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease, Cocaine addiction, Alcoholism D08549 Sulpiride 5件: 2, 6, 17, 46, 70
90 AGTR1 16件: Calcium signaling pathway, cGMP-PKG signaling pathway, Phospholipase D signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Apelin signaling pathway, Renin-angiotensin system, Renin secretion, Aldosterone synthesis and secretion, Cortisol synthesis and secretion, AGE-RAGE signaling pathway in diabetic complications, Cushing syndrome, Coronavirus disease - COVID-19, Pathways in cancer, Diabetic cardiomyopathy D00150 Angiotensin II 7件: 17, 19, 46, 66, 86, 222, 224
91 AGTR1 16件: Calcium signaling pathway, cGMP-PKG signaling pathway, Phospholipase D signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Apelin signaling pathway, Renin-angiotensin system, Renin secretion, Aldosterone synthesis and secretion, Cortisol synthesis and secretion, AGE-RAGE signaling pathway in diabetic complications, Cushing syndrome, Coronavirus disease - COVID-19, Pathways in cancer, Diabetic cardiomyopathy D00357 Losartan 18件: 17, 19, 36, 46, 58, 66, 67, 85, 96, 97, 98, 113, 164, 167, 179, 215, 222, 299
92 AGTR1 16件: Calcium signaling pathway, cGMP-PKG signaling pathway, Phospholipase D signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Apelin signaling pathway, Renin-angiotensin system, Renin secretion, Aldosterone synthesis and secretion, Cortisol synthesis and secretion, AGE-RAGE signaling pathway in diabetic complications, Cushing syndrome, Coronavirus disease - COVID-19, Pathways in cancer, Diabetic cardiomyopathy D02014 Angiotensin II 7件: 17, 19, 46, 66, 86, 222, 224
93 AGTR1 16件: Calcium signaling pathway, cGMP-PKG signaling pathway, Phospholipase D signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Apelin signaling pathway, Renin-angiotensin system, Renin secretion, Aldosterone synthesis and secretion, Cortisol synthesis and secretion, AGE-RAGE signaling pathway in diabetic complications, Cushing syndrome, Coronavirus disease - COVID-19, Pathways in cancer, Diabetic cardiomyopathy D08146 Losartan 18件: 17, 19, 36, 46, 58, 66, 67, 85, 96, 97, 98, 113, 164, 167, 179, 215, 222, 299
94 AGTR2 3件: Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Renin-angiotensin system D00150 Angiotensin II 7件: 17, 19, 46, 66, 86, 222, 224
95 AGTR2 3件: Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Renin-angiotensin system D02014 Angiotensin II 7件: 17, 19, 46, 66, 86, 222, 224
96 DHFR2 5件: One carbon pool by folate, Folate biosynthesis, Metabolic pathways, Biosynthesis of cofactors, Antifolate resistance D00142 Methotrexate 38件: 11, 13, 19, 34, 35, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 53, 55, 56, 60, 62, 65, 84, 93, 96, 97, 107, 162, 164, 172, 256, 270, 271, 283, 284, 285, 286, 326, 331
97 DHFR2 5件: One carbon pool by folate, Folate biosynthesis, Metabolic pathways, Biosynthesis of cofactors, Antifolate resistance D02115 Methotrexate 38件: 11, 13, 19, 34, 35, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 53, 55, 56, 60, 62, 65, 84, 93, 96, 97, 107, 162, 164, 172, 256, 270, 271, 283, 284, 285, 286, 326, 331
98 TUBB 10件: Phagosome, Gap junction, Alzheimer disease, Parkinson disease, Amyotrophic lateral sclerosis, Huntington disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Salmonella infection D00491 Paclitaxel 2件: 46, 85
99 TUBB 10件: Phagosome, Gap junction, Alzheimer disease, Parkinson disease, Amyotrophic lateral sclerosis, Huntington disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Salmonella infection D00570 Colchicine 7件: 2, 42, 46, 56, 93, 210, 266
100 TUBB 10件: Phagosome, Gap junction, Alzheimer disease, Parkinson disease, Amyotrophic lateral sclerosis, Huntington disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Salmonella infection D05333 Paclitaxel 2件: 46, 85
101 EPOR 5件: Cytokine-cytokine receptor interaction, PI3K-Akt signaling pathway, JAK-STAT signaling pathway, Hematopoietic cell lineage, Pathways in cancer D03231 Erythropoietin 10件: 2, 6, 13, 18, 22, 46, 47, 70, 95, 96
102 ESR1 9件: Endocrine resistance, Estrogen signaling pathway, Prolactin signaling pathway, Thyroid hormone signaling pathway, Endocrine and other factor-regulated calcium reabsorption, Pathways in cancer, Proteoglycans in cancer, Chemical carcinogenesis - receptor activation, Breast cancer D00105 Estradiol 7件: 13, 46, 49, 65, 76, 226, 299
103 ESR1 9件: Endocrine resistance, Estrogen signaling pathway, Prolactin signaling pathway, Thyroid hormone signaling pathway, Endocrine and other factor-regulated calcium reabsorption, Pathways in cancer, Proteoglycans in cancer, Chemical carcinogenesis - receptor activation, Breast cancer D00554 Ethinylestradiol 4件: 13, 46, 49, 299
104 ESR1 9件: Endocrine resistance, Estrogen signaling pathway, Prolactin signaling pathway, Thyroid hormone signaling pathway, Endocrine and other factor-regulated calcium reabsorption, Pathways in cancer, Proteoglycans in cancer, Chemical carcinogenesis - receptor activation, Breast cancer D00575 Mestranol 2件: 46, 49
105 ESR1 9件: Endocrine resistance, Estrogen signaling pathway, Prolactin signaling pathway, Thyroid hormone signaling pathway, Endocrine and other factor-regulated calcium reabsorption, Pathways in cancer, Proteoglycans in cancer, Chemical carcinogenesis - receptor activation, Breast cancer D01413 Estradiol 7件: 13, 46, 49, 65, 76, 226, 299
106 ESR1 9件: Endocrine resistance, Estrogen signaling pathway, Prolactin signaling pathway, Thyroid hormone signaling pathway, Endocrine and other factor-regulated calcium reabsorption, Pathways in cancer, Proteoglycans in cancer, Chemical carcinogenesis - receptor activation, Breast cancer D01617 Estradiol 7件: 13, 46, 49, 65, 76, 226, 299
107 ESR1 9件: Endocrine resistance, Estrogen signaling pathway, Prolactin signaling pathway, Thyroid hormone signaling pathway, Endocrine and other factor-regulated calcium reabsorption, Pathways in cancer, Proteoglycans in cancer, Chemical carcinogenesis - receptor activation, Breast cancer D01953 Estradiol 7件: 13, 46, 49, 65, 76, 226, 299
108 ESR1 9件: Endocrine resistance, Estrogen signaling pathway, Prolactin signaling pathway, Thyroid hormone signaling pathway, Endocrine and other factor-regulated calcium reabsorption, Pathways in cancer, Proteoglycans in cancer, Chemical carcinogenesis - receptor activation, Breast cancer D02217 Raloxifene 1件: 46
109 ESR1 9件: Endocrine resistance, Estrogen signaling pathway, Prolactin signaling pathway, Thyroid hormone signaling pathway, Endocrine and other factor-regulated calcium reabsorption, Pathways in cancer, Proteoglycans in cancer, Chemical carcinogenesis - receptor activation, Breast cancer D04061 Estradiol 7件: 13, 46, 49, 65, 76, 226, 299
110 ESR1 9件: Endocrine resistance, Estrogen signaling pathway, Prolactin signaling pathway, Thyroid hormone signaling pathway, Endocrine and other factor-regulated calcium reabsorption, Pathways in cancer, Proteoglycans in cancer, Chemical carcinogenesis - receptor activation, Breast cancer D04063 Estradiol 7件: 13, 46, 49, 65, 76, 226, 299
111 ESR1 9件: Endocrine resistance, Estrogen signaling pathway, Prolactin signaling pathway, Thyroid hormone signaling pathway, Endocrine and other factor-regulated calcium reabsorption, Pathways in cancer, Proteoglycans in cancer, Chemical carcinogenesis - receptor activation, Breast cancer D04064 Estradiol 7件: 13, 46, 49, 65, 76, 226, 299
112 ESR1 9件: Endocrine resistance, Estrogen signaling pathway, Prolactin signaling pathway, Thyroid hormone signaling pathway, Endocrine and other factor-regulated calcium reabsorption, Pathways in cancer, Proteoglycans in cancer, Chemical carcinogenesis - receptor activation, Breast cancer D04065 Estradiol 7件: 13, 46, 49, 65, 76, 226, 299
113 ESR1 9件: Endocrine resistance, Estrogen signaling pathway, Prolactin signaling pathway, Thyroid hormone signaling pathway, Endocrine and other factor-regulated calcium reabsorption, Pathways in cancer, Proteoglycans in cancer, Chemical carcinogenesis - receptor activation, Breast cancer D08465 Raloxifene 1件: 46
114 ESR2 7件: Endocrine resistance, Estrogen signaling pathway, Prolactin signaling pathway, GnRH secretion, Pathways in cancer, Chemical carcinogenesis - receptor activation, Breast cancer D00105 Estradiol 7件: 13, 46, 49, 65, 76, 226, 299
115 ESR2 7件: Endocrine resistance, Estrogen signaling pathway, Prolactin signaling pathway, GnRH secretion, Pathways in cancer, Chemical carcinogenesis - receptor activation, Breast cancer D00575 Mestranol 2件: 46, 49
116 ESR2 7件: Endocrine resistance, Estrogen signaling pathway, Prolactin signaling pathway, GnRH secretion, Pathways in cancer, Chemical carcinogenesis - receptor activation, Breast cancer D01413 Estradiol 7件: 13, 46, 49, 65, 76, 226, 299
117 ESR2 7件: Endocrine resistance, Estrogen signaling pathway, Prolactin signaling pathway, GnRH secretion, Pathways in cancer, Chemical carcinogenesis - receptor activation, Breast cancer D01617 Estradiol 7件: 13, 46, 49, 65, 76, 226, 299
118 ESR2 7件: Endocrine resistance, Estrogen signaling pathway, Prolactin signaling pathway, GnRH secretion, Pathways in cancer, Chemical carcinogenesis - receptor activation, Breast cancer D01953 Estradiol 7件: 13, 46, 49, 65, 76, 226, 299
119 ESR2 7件: Endocrine resistance, Estrogen signaling pathway, Prolactin signaling pathway, GnRH secretion, Pathways in cancer, Chemical carcinogenesis - receptor activation, Breast cancer D02217 Raloxifene 1件: 46
120 ESR2 7件: Endocrine resistance, Estrogen signaling pathway, Prolactin signaling pathway, GnRH secretion, Pathways in cancer, Chemical carcinogenesis - receptor activation, Breast cancer D04061 Estradiol 7件: 13, 46, 49, 65, 76, 226, 299
121 ESR2 7件: Endocrine resistance, Estrogen signaling pathway, Prolactin signaling pathway, GnRH secretion, Pathways in cancer, Chemical carcinogenesis - receptor activation, Breast cancer D04063 Estradiol 7件: 13, 46, 49, 65, 76, 226, 299
122 ESR2 7件: Endocrine resistance, Estrogen signaling pathway, Prolactin signaling pathway, GnRH secretion, Pathways in cancer, Chemical carcinogenesis - receptor activation, Breast cancer D04064 Estradiol 7件: 13, 46, 49, 65, 76, 226, 299
123 ESR2 7件: Endocrine resistance, Estrogen signaling pathway, Prolactin signaling pathway, GnRH secretion, Pathways in cancer, Chemical carcinogenesis - receptor activation, Breast cancer D04065 Estradiol 7件: 13, 46, 49, 65, 76, 226, 299
124 ESR2 7件: Endocrine resistance, Estrogen signaling pathway, Prolactin signaling pathway, GnRH secretion, Pathways in cancer, Chemical carcinogenesis - receptor activation, Breast cancer D08465 Raloxifene 1件: 46
125 F10 1件: Complement and coagulation cascades D07086 Rivaroxaban 5件: 46, 49, 75, 91, 210
126 F10 1件: Complement and coagulation cascades D09710 Edoxaban 2件: 46, 88
127 FCER1A 4件: Sphingolipid signaling pathway, Phospholipase D signaling pathway, Fc epsilon RI signaling pathway, Asthma D05251 Omalizumab 7件: 46, 53, 65, 98, 162, 226, 299
128 FCGRT - D11666 Nipocalimab 4件: 46, 49, 53, 61
129 FDPS 4件: Terpenoid backbone biosynthesis, Metabolic pathways, Influenza A, Human T-cell leukemia virus 1 infection D00939 Alendronic acid 7件: 19, 41, 46, 50, 271, 274, 299
130 FDPS 4件: Terpenoid backbone biosynthesis, Metabolic pathways, Influenza A, Human T-cell leukemia virus 1 infection D00942 Risedronic acid 9件: 46, 50, 66, 93, 95, 96, 107, 113, 274
131 FDPS 4件: Terpenoid backbone biosynthesis, Metabolic pathways, Influenza A, Human T-cell leukemia virus 1 infection D01968 Zoledronic acid 13件: 5, 6, 13, 17, 46, 65, 93, 95, 96, 270, 274, 299, 333
132 FDPS 4件: Terpenoid backbone biosynthesis, Metabolic pathways, Influenza A, Human T-cell leukemia virus 1 infection D03234 Risedronic acid 9件: 46, 50, 66, 93, 95, 96, 107, 113, 274
133 FDPS 4件: Terpenoid backbone biosynthesis, Metabolic pathways, Influenza A, Human T-cell leukemia virus 1 infection D06378 Zoledronic acid 13件: 5, 6, 13, 17, 46, 65, 93, 95, 96, 270, 274, 299, 333
134 FDPS 4件: Terpenoid backbone biosynthesis, Metabolic pathways, Influenza A, Human T-cell leukemia virus 1 infection D06379 Zoledronic acid 13件: 5, 6, 13, 17, 46, 65, 93, 95, 96, 270, 274, 299, 333
135 FDPS 4件: Terpenoid backbone biosynthesis, Metabolic pathways, Influenza A, Human T-cell leukemia virus 1 infection D07119 Alendronic acid 7件: 19, 41, 46, 50, 271, 274, 299
136 FDPS 4件: Terpenoid backbone biosynthesis, Metabolic pathways, Influenza A, Human T-cell leukemia virus 1 infection D08056 Ibandronate 3件: 46, 49, 274
137 FDPS 4件: Terpenoid backbone biosynthesis, Metabolic pathways, Influenza A, Human T-cell leukemia virus 1 infection D08484 Risedronic acid 9件: 46, 50, 66, 93, 95, 96, 107, 113, 274
138 FDPS 4件: Terpenoid backbone biosynthesis, Metabolic pathways, Influenza A, Human T-cell leukemia virus 1 infection D08689 Zoledronic acid 13件: 5, 6, 13, 17, 46, 65, 93, 95, 96, 270, 274, 299, 333
139 FLT1 2件: Transcriptional misregulation in cancer, Rheumatoid arthritis D03218 Axitinib 1件: 34
140 FLT1 2件: Transcriptional misregulation in cancer, Rheumatoid arthritis D06402 Sunitinib 2件: 28, 34
141 FLT1 2件: Transcriptional misregulation in cancer, Rheumatoid arthritis D08552 Sunitinib 2件: 28, 34
142 FLT1 2件: Transcriptional misregulation in cancer, Rheumatoid arthritis D08881 Cediranib 1件: 34
143 FLT1 2件: Transcriptional misregulation in cancer, Rheumatoid arthritis D10481 Nintedanib 5件: 51, 85, 89, 227, 228
144 POLA2 1件: DNA replication D03546 Clofarabine 6件: 46, 49, 60, 96, 234, 326
145 MTOR 51件: EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, ErbB signaling pathway, HIF-1 signaling pathway, Phospholipase D signaling pathway, Autophagy - other, Autophagy - animal, mTOR signaling pathway, PI3K-Akt signaling pathway, AMPK signaling pathway, Longevity regulating pathway, Longevity regulating pathway - multiple species, Cellular senescence, Apelin signaling pathway, Neutrophil extracellular trap formation, JAK-STAT signaling pathway, Th17 cell differentiation, Thermogenesis, Insulin signaling pathway, Thyroid hormone signaling pathway, Adipocytokine signaling pathway, Type II diabetes mellitus, Insulin resistance, Growth hormone synthesis, secretion and action, Alzheimer disease, Amyotrophic lateral sclerosis, Huntington disease, Spinocerebellar ataxia, Pathways of neurodegeneration - multiple diseases, Shigellosis, Human cytomegalovirus infection, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Human immunodeficiency virus 1 infection, Pathways in cancer, Proteoglycans in cancer, MicroRNAs in cancer, Chemical carcinogenesis - receptor activation, Colorectal cancer, Pancreatic cancer, Glioma, Prostate cancer, Acute myeloid leukemia, Breast cancer, Hepatocellular carcinoma, Gastric cancer, Central carbon metabolism in cancer, Choline metabolism in cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer, Diabetic cardiomyopathy D00753 Sirolimus 41件: 2, 6, 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331
146 GABRA1 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D00267 Chlordiazepoxide 1件: 46
147 GABRA1 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D00293 Diazepam 3件: 46, 155, 298
148 GABRA1 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D00549 Propofol 10件: 6, 21, 22, 34, 46, 70, 75, 84, 98, 296
149 GABRA1 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D00550 Midazolam 12件: 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
150 GABRA1 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D00693 Chlordiazepoxide 1件: 46
151 GABRA1 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D00696 Midazolam 12件: 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
152 GABRA1 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D00706 Zolpidem 3件: 5, 6, 46
153 GABRA1 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D01514 Etizolam 1件: 46
154 GABRA1 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D02624 Eszopiclone 3件: 6, 13, 46
155 GABRA1 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D05028 Midazolam 12件: 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
156 GABRA1 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D07784 Delorazepam 3件: 6, 46, 97
157 GABRA1 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D08690 Zolpidem 3件: 5, 6, 46
158 GABRA2 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D00267 Chlordiazepoxide 1件: 46
159 GABRA2 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D00293 Diazepam 3件: 46, 155, 298
160 GABRA2 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D00549 Propofol 10件: 6, 21, 22, 34, 46, 70, 75, 84, 98, 296
161 GABRA2 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D00550 Midazolam 12件: 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
162 GABRA2 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D00693 Chlordiazepoxide 1件: 46
163 GABRA2 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D00696 Midazolam 12件: 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
164 GABRA2 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D00706 Zolpidem 3件: 5, 6, 46
165 GABRA2 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D01514 Etizolam 1件: 46
166 GABRA2 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D02624 Eszopiclone 3件: 6, 13, 46
167 GABRA2 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D05028 Midazolam 12件: 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
168 GABRA2 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D07784 Delorazepam 3件: 6, 46, 97
169 GABRA2 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D08690 Zolpidem 3件: 5, 6, 46
170 GABRA3 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D00267 Chlordiazepoxide 1件: 46
171 GABRA3 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D00293 Diazepam 3件: 46, 155, 298
172 GABRA3 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D00549 Propofol 10件: 6, 21, 22, 34, 46, 70, 75, 84, 98, 296
173 GABRA3 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D00550 Midazolam 12件: 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
174 GABRA3 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D00693 Chlordiazepoxide 1件: 46
175 GABRA3 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D00696 Midazolam 12件: 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
176 GABRA3 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D00706 Zolpidem 3件: 5, 6, 46
177 GABRA3 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D01514 Etizolam 1件: 46
178 GABRA3 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D02624 Eszopiclone 3件: 6, 13, 46
179 GABRA3 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D05028 Midazolam 12件: 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
180 GABRA3 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D07784 Delorazepam 3件: 6, 46, 97
181 GABRA3 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D08690 Zolpidem 3件: 5, 6, 46
182 GABRA4 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D00267 Chlordiazepoxide 1件: 46
183 GABRA4 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D00293 Diazepam 3件: 46, 155, 298
184 GABRA4 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D00549 Propofol 10件: 6, 21, 22, 34, 46, 70, 75, 84, 98, 296
185 GABRA4 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D00550 Midazolam 12件: 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
186 GABRA4 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D00693 Chlordiazepoxide 1件: 46
187 GABRA4 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D00696 Midazolam 12件: 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
188 GABRA4 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D00706 Zolpidem 3件: 5, 6, 46
189 GABRA4 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D01514 Etizolam 1件: 46
190 GABRA4 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D02624 Eszopiclone 3件: 6, 13, 46
191 GABRA4 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D05028 Midazolam 12件: 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
192 GABRA4 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D07784 Delorazepam 3件: 6, 46, 97
193 GABRA4 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D08690 Zolpidem 3件: 5, 6, 46
194 GABRA5 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D00267 Chlordiazepoxide 1件: 46
195 GABRA5 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D00293 Diazepam 3件: 46, 155, 298
196 GABRA5 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D00549 Propofol 10件: 6, 21, 22, 34, 46, 70, 75, 84, 98, 296
197 GABRA5 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D00550 Midazolam 12件: 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
198 GABRA5 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D00693 Chlordiazepoxide 1件: 46
199 GABRA5 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D00696 Midazolam 12件: 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
200 GABRA5 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D00706 Zolpidem 3件: 5, 6, 46
201 GABRA5 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D01514 Etizolam 1件: 46
202 GABRA5 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D02624 Eszopiclone 3件: 6, 13, 46
203 GABRA5 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D05028 Midazolam 12件: 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
204 GABRA5 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D07784 Delorazepam 3件: 6, 46, 97
205 GABRA5 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D08690 Zolpidem 3件: 5, 6, 46
206 GABRA6 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D00267 Chlordiazepoxide 1件: 46
207 GABRA6 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D00293 Diazepam 3件: 46, 155, 298
208 GABRA6 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D00549 Propofol 10件: 6, 21, 22, 34, 46, 70, 75, 84, 98, 296
209 GABRA6 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D00550 Midazolam 12件: 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
210 GABRA6 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D00693 Chlordiazepoxide 1件: 46
211 GABRA6 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D00696 Midazolam 12件: 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
212 GABRA6 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D00706 Zolpidem 3件: 5, 6, 46
213 GABRA6 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D01514 Etizolam 1件: 46
214 GABRA6 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D02624 Eszopiclone 3件: 6, 13, 46
215 GABRA6 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D05028 Midazolam 12件: 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
216 GABRA6 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D07784 Delorazepam 3件: 6, 46, 97
217 GABRA6 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D08690 Zolpidem 3件: 5, 6, 46
218 GABRB1 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Morphine addiction, Nicotine addiction D00267 Chlordiazepoxide 1件: 46
219 GABRB1 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Morphine addiction, Nicotine addiction D00293 Diazepam 3件: 46, 155, 298
220 GABRB1 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Morphine addiction, Nicotine addiction D00549 Propofol 10件: 6, 21, 22, 34, 46, 70, 75, 84, 98, 296
221 GABRB1 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Morphine addiction, Nicotine addiction D00550 Midazolam 12件: 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
222 GABRB1 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Morphine addiction, Nicotine addiction D00693 Chlordiazepoxide 1件: 46
223 GABRB1 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Morphine addiction, Nicotine addiction D00696 Midazolam 12件: 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
224 GABRB1 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Morphine addiction, Nicotine addiction D00706 Zolpidem 3件: 5, 6, 46
225 GABRB1 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Morphine addiction, Nicotine addiction D01514 Etizolam 1件: 46
226 GABRB1 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Morphine addiction, Nicotine addiction D02624 Eszopiclone 3件: 6, 13, 46
227 GABRB1 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Morphine addiction, Nicotine addiction D05028 Midazolam 12件: 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
228 GABRB1 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Morphine addiction, Nicotine addiction D07784 Delorazepam 3件: 6, 46, 97
229 GABRB1 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Morphine addiction, Nicotine addiction D08690 Zolpidem 3件: 5, 6, 46
230 GABRB2 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Morphine addiction, Nicotine addiction D00267 Chlordiazepoxide 1件: 46
231 GABRB2 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Morphine addiction, Nicotine addiction D00293 Diazepam 3件: 46, 155, 298
232 GABRB2 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Morphine addiction, Nicotine addiction D00549 Propofol 10件: 6, 21, 22, 34, 46, 70, 75, 84, 98, 296
233 GABRB2 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Morphine addiction, Nicotine addiction D00550 Midazolam 12件: 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
234 GABRB2 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Morphine addiction, Nicotine addiction D00693 Chlordiazepoxide 1件: 46
235 GABRB2 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Morphine addiction, Nicotine addiction D00696 Midazolam 12件: 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
236 GABRB2 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Morphine addiction, Nicotine addiction D00706 Zolpidem 3件: 5, 6, 46
237 GABRB2 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Morphine addiction, Nicotine addiction D01514 Etizolam 1件: 46
238 GABRB2 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Morphine addiction, Nicotine addiction D02624 Eszopiclone 3件: 6, 13, 46
239 GABRB2 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Morphine addiction, Nicotine addiction D05028 Midazolam 12件: 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
240 GABRB2 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Morphine addiction, Nicotine addiction D07784 Delorazepam 3件: 6, 46, 97
241 GABRB2 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Morphine addiction, Nicotine addiction D08690 Zolpidem 3件: 5, 6, 46
242 GABRB3 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Morphine addiction, Nicotine addiction D00267 Chlordiazepoxide 1件: 46
243 GABRB3 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Morphine addiction, Nicotine addiction D00293 Diazepam 3件: 46, 155, 298
244 GABRB3 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Morphine addiction, Nicotine addiction D00549 Propofol 10件: 6, 21, 22, 34, 46, 70, 75, 84, 98, 296
245 GABRB3 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Morphine addiction, Nicotine addiction D00550 Midazolam 12件: 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
246 GABRB3 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Morphine addiction, Nicotine addiction D00693 Chlordiazepoxide 1件: 46
247 GABRB3 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Morphine addiction, Nicotine addiction D00696 Midazolam 12件: 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
248 GABRB3 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Morphine addiction, Nicotine addiction D00706 Zolpidem 3件: 5, 6, 46
249 GABRB3 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Morphine addiction, Nicotine addiction D01514 Etizolam 1件: 46
250 GABRB3 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Morphine addiction, Nicotine addiction D02624 Eszopiclone 3件: 6, 13, 46
251 GABRB3 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Morphine addiction, Nicotine addiction D05028 Midazolam 12件: 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
252 GABRB3 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Morphine addiction, Nicotine addiction D07784 Delorazepam 3件: 6, 46, 97
253 GABRB3 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Morphine addiction, Nicotine addiction D08690 Zolpidem 3件: 5, 6, 46
254 GABRD 5件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D00267 Chlordiazepoxide 1件: 46
255 GABRD 5件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D00293 Diazepam 3件: 46, 155, 298
256 GABRD 5件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D00549 Propofol 10件: 6, 21, 22, 34, 46, 70, 75, 84, 98, 296
257 GABRD 5件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D00550 Midazolam 12件: 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
258 GABRD 5件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D00693 Chlordiazepoxide 1件: 46
259 GABRD 5件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D00696 Midazolam 12件: 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
260 GABRD 5件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D00706 Zolpidem 3件: 5, 6, 46
261 GABRD 5件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D01514 Etizolam 1件: 46
262 GABRD 5件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D02624 Eszopiclone 3件: 6, 13, 46
263 GABRD 5件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D05028 Midazolam 12件: 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
264 GABRD 5件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D07784 Delorazepam 3件: 6, 46, 97
265 GABRD 5件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D08690 Zolpidem 3件: 5, 6, 46
266 GABRE 5件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D00267 Chlordiazepoxide 1件: 46
267 GABRE 5件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D00293 Diazepam 3件: 46, 155, 298
268 GABRE 5件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D00549 Propofol 10件: 6, 21, 22, 34, 46, 70, 75, 84, 98, 296
269 GABRE 5件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D00550 Midazolam 12件: 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
270 GABRE 5件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D00693 Chlordiazepoxide 1件: 46
271 GABRE 5件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D00696 Midazolam 12件: 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
272 GABRE 5件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D00706 Zolpidem 3件: 5, 6, 46
273 GABRE 5件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D01514 Etizolam 1件: 46
274 GABRE 5件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D02624 Eszopiclone 3件: 6, 13, 46
275 GABRE 5件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D05028 Midazolam 12件: 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
276 GABRE 5件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D07784 Delorazepam 3件: 6, 46, 97
277 GABRE 5件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D08690 Zolpidem 3件: 5, 6, 46
278 GABRG1 5件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D00267 Chlordiazepoxide 1件: 46
279 GABRG1 5件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D00293 Diazepam 3件: 46, 155, 298
280 GABRG1 5件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D00549 Propofol 10件: 6, 21, 22, 34, 46, 70, 75, 84, 98, 296
281 GABRG1 5件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D00550 Midazolam 12件: 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
282 GABRG1 5件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D00693 Chlordiazepoxide 1件: 46
283 GABRG1 5件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D00696 Midazolam 12件: 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
284 GABRG1 5件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D00706 Zolpidem 3件: 5, 6, 46
285 GABRG1 5件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D01514 Etizolam 1件: 46
286 GABRG1 5件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D02624 Eszopiclone 3件: 6, 13, 46
287 GABRG1 5件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D05028 Midazolam 12件: 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
288 GABRG1 5件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D07784 Delorazepam 3件: 6, 46, 97
289 GABRG1 5件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D08690 Zolpidem 3件: 5, 6, 46
290 GABRG2 5件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D00267 Chlordiazepoxide 1件: 46
291 GABRG2 5件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D00293 Diazepam 3件: 46, 155, 298
292 GABRG2 5件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D00549 Propofol 10件: 6, 21, 22, 34, 46, 70, 75, 84, 98, 296
293 GABRG2 5件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D00550 Midazolam 12件: 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
294 GABRG2 5件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D00693 Chlordiazepoxide 1件: 46
295 GABRG2 5件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D00696 Midazolam 12件: 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
296 GABRG2 5件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D00706 Zolpidem 3件: 5, 6, 46
297 GABRG2 5件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D01514 Etizolam 1件: 46
298 GABRG2 5件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D02624 Eszopiclone 3件: 6, 13, 46
299 GABRG2 5件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D05028 Midazolam 12件: 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
300 GABRG2 5件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D07784 Delorazepam 3件: 6, 46, 97
301 GABRG2 5件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D08690 Zolpidem 3件: 5, 6, 46
302 GABRG3 5件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D00267 Chlordiazepoxide 1件: 46
303 GABRG3 5件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D00293 Diazepam 3件: 46, 155, 298
304 GABRG3 5件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D00549 Propofol 10件: 6, 21, 22, 34, 46, 70, 75, 84, 98, 296
305 GABRG3 5件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D00550 Midazolam 12件: 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
306 GABRG3 5件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D00693 Chlordiazepoxide 1件: 46
307 GABRG3 5件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D00696 Midazolam 12件: 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
308 GABRG3 5件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D00706 Zolpidem 3件: 5, 6, 46
309 GABRG3 5件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D01514 Etizolam 1件: 46
310 GABRG3 5件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D02624 Eszopiclone 3件: 6, 13, 46
311 GABRG3 5件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D05028 Midazolam 12件: 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
312 GABRG3 5件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D07784 Delorazepam 3件: 6, 46, 97
313 GABRG3 5件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D08690 Zolpidem 3件: 5, 6, 46
314 GABRP 5件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D00267 Chlordiazepoxide 1件: 46
315 GABRP 5件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D00293 Diazepam 3件: 46, 155, 298
316 GABRP 5件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D00549 Propofol 10件: 6, 21, 22, 34, 46, 70, 75, 84, 98, 296
317 GABRP 5件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D00550 Midazolam 12件: 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
318 GABRP 5件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D00693 Chlordiazepoxide 1件: 46
319 GABRP 5件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D00696 Midazolam 12件: 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
320 GABRP 5件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D00706 Zolpidem 3件: 5, 6, 46
321 GABRP 5件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D01514 Etizolam 1件: 46
322 GABRP 5件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D02624 Eszopiclone 3件: 6, 13, 46
323 GABRP 5件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D05028 Midazolam 12件: 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
324 GABRP 5件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D07784 Delorazepam 3件: 6, 46, 97
325 GABRP 5件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D08690 Zolpidem 3件: 5, 6, 46
326 ABL1 11件: ErbB signaling pathway, Ras signaling pathway, Cell cycle, Axon guidance, Neurotrophin signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, MicroRNAs in cancer, Chemical carcinogenesis - reactive oxygen species, Chronic myeloid leukemia, Viral myocarditis D01441 Imatinib 12件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162
327 ABL1 11件: ErbB signaling pathway, Ras signaling pathway, Cell cycle, Axon guidance, Neurotrophin signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, MicroRNAs in cancer, Chemical carcinogenesis - reactive oxygen species, Chronic myeloid leukemia, Viral myocarditis D08066 Imatinib 12件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162
328 GHR 5件: Cytokine-cytokine receptor interaction, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, JAK-STAT signaling pathway, Growth hormone synthesis, secretion and action D02691 Somatotropin 23件: 2, 3, 13, 19, 46, 65, 74, 75, 76, 78, 96, 107, 113, 187, 191, 193, 195, 236, 238, 265, 274, 276, 299
329 GNRHR 2件: Neuroactive ligand-receptor interaction, GnRH signaling pathway D01685 Cetrorelix 1件: 46
330 GNRHR 2件: Neuroactive ligand-receptor interaction, GnRH signaling pathway D07665 Cetrorelix 1件: 46
331 GRIN1 18件: Ras signaling pathway, Rap1 signaling pathway, Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Huntington disease, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism D00848 Dextromethorphan 11件: 2, 6, 8, 13, 21, 46, 78, 85, 96, 97, 156
332 GRIN1 18件: Ras signaling pathway, Rap1 signaling pathway, Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Huntington disease, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism D03742 Dextromethorphan 11件: 2, 6, 8, 13, 21, 46, 78, 85, 96, 97, 156
333 GRIN1 18件: Ras signaling pathway, Rap1 signaling pathway, Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Huntington disease, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism D03744 Dextromethorphan 11件: 2, 6, 8, 13, 21, 46, 78, 85, 96, 97, 156
334 GRIN2A 19件: Ras signaling pathway, Rap1 signaling pathway, Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism, Systemic lupus erythematosus D00848 Dextromethorphan 11件: 2, 6, 8, 13, 21, 46, 78, 85, 96, 97, 156
335 GRIN2A 19件: Ras signaling pathway, Rap1 signaling pathway, Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism, Systemic lupus erythematosus D03742 Dextromethorphan 11件: 2, 6, 8, 13, 21, 46, 78, 85, 96, 97, 156
336 GRIN2A 19件: Ras signaling pathway, Rap1 signaling pathway, Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism, Systemic lupus erythematosus D03744 Dextromethorphan 11件: 2, 6, 8, 13, 21, 46, 78, 85, 96, 97, 156
337 GRIN2B 19件: Ras signaling pathway, Rap1 signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Huntington disease, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism, Systemic lupus erythematosus D00848 Dextromethorphan 11件: 2, 6, 8, 13, 21, 46, 78, 85, 96, 97, 156
338 GRIN2B 19件: Ras signaling pathway, Rap1 signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Huntington disease, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism, Systemic lupus erythematosus D03742 Dextromethorphan 11件: 2, 6, 8, 13, 21, 46, 78, 85, 96, 97, 156
339 GRIN2B 19件: Ras signaling pathway, Rap1 signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Huntington disease, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism, Systemic lupus erythematosus D03744 Dextromethorphan 11件: 2, 6, 8, 13, 21, 46, 78, 85, 96, 97, 156
340 GRIN2C 15件: Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism D00848 Dextromethorphan 11件: 2, 6, 8, 13, 21, 46, 78, 85, 96, 97, 156
341 GRIN2C 15件: Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism D03742 Dextromethorphan 11件: 2, 6, 8, 13, 21, 46, 78, 85, 96, 97, 156
342 GRIN2C 15件: Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism D03744 Dextromethorphan 11件: 2, 6, 8, 13, 21, 46, 78, 85, 96, 97, 156
343 GRIN2D 15件: Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism D00848 Dextromethorphan 11件: 2, 6, 8, 13, 21, 46, 78, 85, 96, 97, 156
344 GRIN2D 15件: Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism D03742 Dextromethorphan 11件: 2, 6, 8, 13, 21, 46, 78, 85, 96, 97, 156
345 GRIN2D 15件: Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism D03744 Dextromethorphan 11件: 2, 6, 8, 13, 21, 46, 78, 85, 96, 97, 156
346 NR3C1 1件: Neuroactive ligand-receptor interaction D00088 Hydrocortisone 9件: 46, 53, 75, 78, 81, 83, 97, 98, 299
347 NR3C1 1件: Neuroactive ligand-receptor interaction D00244 Betamethasone 5件: 46, 83, 90, 96, 235
348 NR3C1 1件: Neuroactive ligand-receptor interaction D00292 Dexamethasone 20件: 46, 53, 63, 64, 65, 70, 74, 75, 81, 84, 90, 96, 97, 162, 222, 235, 257, 283, 296, 299
349 NR3C1 1件: Neuroactive ligand-receptor interaction D00385 Triamcinolone 9件: 46, 56, 70, 90, 96, 107, 162, 226, 298
350 NR3C1 1件: Neuroactive ligand-receptor interaction D00407 Methylprednisolone 31件: 46, 49, 50, 51, 60, 62, 63, 64, 65, 66, 83, 84, 86, 93, 95, 96, 97, 127, 145, 162, 164, 211, 220, 222, 224, 271, 283, 284, 285, 296, 300
351 NR3C1 1件: Neuroactive ligand-receptor interaction D00472 Prednisolone 29件: 46, 49, 50, 51, 56, 60, 61, 63, 64, 65, 66, 75, 81, 84, 85, 95, 96, 97, 107, 113, 145, 162, 222, 269, 271, 296, 299, 300, 307
352 NR3C1 1件: Neuroactive ligand-receptor interaction D00473 Prednisone 34件: 46, 49, 50, 51, 53, 61, 63, 64, 65, 66, 79, 81, 84, 85, 86, 95, 96, 97, 113, 127, 162, 164, 205, 222, 224, 228, 251, 283, 284, 285, 288, 299, 300, 331
353 NR3C1 1件: Neuroactive ligand-receptor interaction D00751 Methylprednisolone 31件: 46, 49, 50, 51, 60, 62, 63, 64, 65, 66, 83, 84, 86, 93, 95, 96, 97, 127, 145, 162, 164, 211, 220, 222, 224, 271, 283, 284, 285, 296, 300
354 NR3C1 1件: Neuroactive ligand-receptor interaction D00972 Betamethasone 5件: 46, 83, 90, 96, 235
355 NR3C1 1件: Neuroactive ligand-receptor interaction D00975 Dexamethasone 20件: 46, 53, 63, 64, 65, 70, 74, 75, 81, 84, 90, 96, 97, 162, 222, 235, 257, 283, 296, 299
356 NR3C1 1件: Neuroactive ligand-receptor interaction D00979 Methylprednisolone 31件: 46, 49, 50, 51, 60, 62, 63, 64, 65, 66, 83, 84, 86, 93, 95, 96, 97, 127, 145, 162, 164, 211, 220, 222, 224, 271, 283, 284, 285, 296, 300
357 NR3C1 1件: Neuroactive ligand-receptor interaction D00980 Prednisolone 29件: 46, 49, 50, 51, 56, 60, 61, 63, 64, 65, 66, 75, 81, 84, 85, 95, 96, 97, 107, 113, 145, 162, 222, 269, 271, 296, 299, 300, 307
358 NR3C1 1件: Neuroactive ligand-receptor interaction D00981 Prednisolone 29件: 46, 49, 50, 51, 56, 60, 61, 63, 64, 65, 66, 75, 81, 84, 85, 95, 96, 97, 107, 113, 145, 162, 222, 269, 271, 296, 299, 300, 307
359 NR3C1 1件: Neuroactive ligand-receptor interaction D00982 Prednisolone 29件: 46, 49, 50, 51, 56, 60, 61, 63, 64, 65, 66, 75, 81, 84, 85, 95, 96, 97, 107, 113, 145, 162, 222, 269, 271, 296, 299, 300, 307
360 NR3C1 1件: Neuroactive ligand-receptor interaction D00983 Triamcinolone 9件: 46, 56, 70, 90, 96, 107, 162, 226, 298
361 NR3C1 1件: Neuroactive ligand-receptor interaction D00984 Triamcinolone 9件: 46, 56, 70, 90, 96, 107, 162, 226, 298
362 NR3C1 1件: Neuroactive ligand-receptor interaction D00985 Triamcinolone 9件: 46, 56, 70, 90, 96, 107, 162, 226, 298
363 NR3C1 1件: Neuroactive ligand-receptor interaction D01239 Prednisolone 29件: 46, 49, 50, 51, 56, 60, 61, 63, 64, 65, 66, 75, 81, 84, 85, 95, 96, 97, 107, 113, 145, 162, 222, 269, 271, 296, 299, 300, 307
364 NR3C1 1件: Neuroactive ligand-receptor interaction D01272 Clobetasol propionate 2件: 46, 162
365 NR3C1 1件: Neuroactive ligand-receptor interaction D01357 Betamethasone 5件: 46, 83, 90, 96, 235
366 NR3C1 1件: Neuroactive ligand-receptor interaction D01402 Betamethasone 5件: 46, 83, 90, 96, 235
367 NR3C1 1件: Neuroactive ligand-receptor interaction D01510 Dexamethasone 20件: 46, 53, 63, 64, 65, 70, 74, 75, 81, 84, 90, 96, 97, 162, 222, 235, 257, 283, 296, 299
368 NR3C1 1件: Neuroactive ligand-receptor interaction D01615 Dexamethasone 20件: 46, 53, 63, 64, 65, 70, 74, 75, 81, 84, 90, 96, 97, 162, 222, 235, 257, 283, 296, 299
369 NR3C1 1件: Neuroactive ligand-receptor interaction D01632 Dexamethasone 20件: 46, 53, 63, 64, 65, 70, 74, 75, 81, 84, 90, 96, 97, 162, 222, 235, 257, 283, 296, 299
370 NR3C1 1件: Neuroactive ligand-receptor interaction D01637 Betamethasone 5件: 46, 83, 90, 96, 235
371 NR3C1 1件: Neuroactive ligand-receptor interaction D01948 Dexamethasone 20件: 46, 53, 63, 64, 65, 70, 74, 75, 81, 84, 90, 96, 97, 162, 222, 235, 257, 283, 296, 299
372 NR3C1 1件: Neuroactive ligand-receptor interaction D01998 Prednisolone 29件: 46, 49, 50, 51, 56, 60, 61, 63, 64, 65, 66, 75, 81, 84, 85, 95, 96, 97, 107, 113, 145, 162, 222, 269, 271, 296, 299, 300, 307
373 NR3C1 1件: Neuroactive ligand-receptor interaction D02032 Betamethasone 5件: 46, 83, 90, 96, 235
374 NR3C1 1件: Neuroactive ligand-receptor interaction D02156 Prednisolone 29件: 46, 49, 50, 51, 56, 60, 61, 63, 64, 65, 66, 75, 81, 84, 85, 95, 96, 97, 107, 113, 145, 162, 222, 269, 271, 296, 299, 300, 307
375 NR3C1 1件: Neuroactive ligand-receptor interaction D02174 Dexamethasone 20件: 46, 53, 63, 64, 65, 70, 74, 75, 81, 84, 90, 96, 97, 162, 222, 235, 257, 283, 296, 299
376 NR3C1 1件: Neuroactive ligand-receptor interaction D02286 Betamethasone 5件: 46, 83, 90, 96, 235
377 NR3C1 1件: Neuroactive ligand-receptor interaction D02591 Dexamethasone 20件: 46, 53, 63, 64, 65, 70, 74, 75, 81, 84, 90, 96, 97, 162, 222, 235, 257, 283, 296, 299
378 NR3C1 1件: Neuroactive ligand-receptor interaction D02592 Dexamethasone 20件: 46, 53, 63, 64, 65, 70, 74, 75, 81, 84, 90, 96, 97, 162, 222, 235, 257, 283, 296, 299
379 NR3C1 1件: Neuroactive ligand-receptor interaction D03301 Prednisolone 29件: 46, 49, 50, 51, 56, 60, 61, 63, 64, 65, 66, 75, 81, 84, 85, 95, 96, 97, 107, 113, 145, 162, 222, 269, 271, 296, 299, 300, 307
380 NR3C1 1件: Neuroactive ligand-receptor interaction D05000 Methylprednisolone 31件: 46, 49, 50, 51, 60, 62, 63, 64, 65, 66, 83, 84, 86, 93, 95, 96, 97, 127, 145, 162, 164, 211, 220, 222, 224, 271, 283, 284, 285, 296, 300
381 NR3C1 1件: Neuroactive ligand-receptor interaction D05001 Methylprednisolone 31件: 46, 49, 50, 51, 60, 62, 63, 64, 65, 66, 83, 84, 86, 93, 95, 96, 97, 127, 145, 162, 164, 211, 220, 222, 224, 271, 283, 284, 285, 296, 300
382 NR3C1 1件: Neuroactive ligand-receptor interaction D05002 Methylprednisolone 31件: 46, 49, 50, 51, 60, 62, 63, 64, 65, 66, 83, 84, 86, 93, 95, 96, 97, 127, 145, 162, 164, 211, 220, 222, 224, 271, 283, 284, 285, 296, 300
383 NR3C1 1件: Neuroactive ligand-receptor interaction D06216 Triamcinolone 9件: 46, 56, 70, 90, 96, 107, 162, 226, 298
384 NR3C1 1件: Neuroactive ligand-receptor interaction D07715 Clobetasol propionate 2件: 46, 162
385 NR3C1 1件: Neuroactive ligand-receptor interaction D07715 Clobetasol 3件: 46, 51, 162
386 NR3C1 1件: Neuroactive ligand-receptor interaction D08416 Prednisone acetate 4件: 46, 49, 162, 224
387 HLA-DMA 9件: Th1 and Th2 cell differentiation, Th17 cell differentiation, Type I diabetes mellitus, Toxoplasmosis, Staphylococcus aureus infection, Tuberculosis, Systemic lupus erythematosus, Rheumatoid arthritis, Viral myocarditis D04318 Glatiramer 4件: 2, 13, 96, 156
388 HLA-DMB 9件: Th1 and Th2 cell differentiation, Th17 cell differentiation, Type I diabetes mellitus, Toxoplasmosis, Staphylococcus aureus infection, Tuberculosis, Systemic lupus erythematosus, Rheumatoid arthritis, Viral myocarditis D04318 Glatiramer 4件: 2, 13, 96, 156
389 HLA-DOA 9件: Th1 and Th2 cell differentiation, Th17 cell differentiation, Type I diabetes mellitus, Toxoplasmosis, Staphylococcus aureus infection, Tuberculosis, Systemic lupus erythematosus, Rheumatoid arthritis, Viral myocarditis D04318 Glatiramer 4件: 2, 13, 96, 156
390 HLA-DOB 9件: Th1 and Th2 cell differentiation, Th17 cell differentiation, Type I diabetes mellitus, Toxoplasmosis, Staphylococcus aureus infection, Tuberculosis, Systemic lupus erythematosus, Rheumatoid arthritis, Viral myocarditis D04318 Glatiramer 4件: 2, 13, 96, 156
391 HLA-DPA1 9件: Th1 and Th2 cell differentiation, Th17 cell differentiation, Type I diabetes mellitus, Toxoplasmosis, Staphylococcus aureus infection, Tuberculosis, Systemic lupus erythematosus, Rheumatoid arthritis, Viral myocarditis D04318 Glatiramer 4件: 2, 13, 96, 156
392 HLA-DPB1 9件: Th1 and Th2 cell differentiation, Th17 cell differentiation, Type I diabetes mellitus, Toxoplasmosis, Staphylococcus aureus infection, Tuberculosis, Systemic lupus erythematosus, Rheumatoid arthritis, Viral myocarditis D04318 Glatiramer 4件: 2, 13, 96, 156
393 HLA-DQA1 9件: Th1 and Th2 cell differentiation, Th17 cell differentiation, Type I diabetes mellitus, Toxoplasmosis, Staphylococcus aureus infection, Tuberculosis, Systemic lupus erythematosus, Rheumatoid arthritis, Viral myocarditis D04318 Glatiramer 4件: 2, 13, 96, 156
394 HLA-DQA2 9件: Th1 and Th2 cell differentiation, Th17 cell differentiation, Type I diabetes mellitus, Toxoplasmosis, Staphylococcus aureus infection, Tuberculosis, Systemic lupus erythematosus, Rheumatoid arthritis, Viral myocarditis D04318 Glatiramer 4件: 2, 13, 96, 156
395 HLA-DQB1 9件: Th1 and Th2 cell differentiation, Th17 cell differentiation, Type I diabetes mellitus, Toxoplasmosis, Staphylococcus aureus infection, Tuberculosis, Systemic lupus erythematosus, Rheumatoid arthritis, Viral myocarditis D04318 Glatiramer 4件: 2, 13, 96, 156
396 HLA-DRA 9件: Th1 and Th2 cell differentiation, Th17 cell differentiation, Type I diabetes mellitus, Toxoplasmosis, Staphylococcus aureus infection, Tuberculosis, Systemic lupus erythematosus, Rheumatoid arthritis, Viral myocarditis D04318 Glatiramer 4件: 2, 13, 96, 156
397 HLA-DRB1 9件: Th1 and Th2 cell differentiation, Th17 cell differentiation, Type I diabetes mellitus, Toxoplasmosis, Staphylococcus aureus infection, Tuberculosis, Systemic lupus erythematosus, Rheumatoid arthritis, Viral myocarditis D04318 Glatiramer 4件: 2, 13, 96, 156
398 HLA-DRB3 9件: Th1 and Th2 cell differentiation, Th17 cell differentiation, Type I diabetes mellitus, Toxoplasmosis, Staphylococcus aureus infection, Tuberculosis, Systemic lupus erythematosus, Rheumatoid arthritis, Viral myocarditis D04318 Glatiramer 4件: 2, 13, 96, 156
399 HLA-DRB4 9件: Th1 and Th2 cell differentiation, Th17 cell differentiation, Type I diabetes mellitus, Toxoplasmosis, Staphylococcus aureus infection, Tuberculosis, Systemic lupus erythematosus, Rheumatoid arthritis, Viral myocarditis D04318 Glatiramer 4件: 2, 13, 96, 156
400 HLA-DRB5 9件: Th1 and Th2 cell differentiation, Th17 cell differentiation, Type I diabetes mellitus, Toxoplasmosis, Staphylococcus aureus infection, Tuberculosis, Systemic lupus erythematosus, Rheumatoid arthritis, Viral myocarditis D04318 Glatiramer 4件: 2, 13, 96, 156
401 HMGCR 4件: Terpenoid backbone biosynthesis, Metabolic pathways, AMPK signaling pathway, Bile secretion D00359 Lovastatin 11件: 6, 34, 46, 79, 156, 160, 195, 206, 263, 280, 310
402 HMGCR 4件: Terpenoid backbone biosynthesis, Metabolic pathways, AMPK signaling pathway, Bile secretion D00434 Simvastatin 21件: 6, 13, 15, 34, 46, 49, 51, 66, 79, 86, 89, 94, 158, 160, 162, 195, 265, 288, 298, 299, 310
403 HMGCR 4件: Terpenoid backbone biosynthesis, Metabolic pathways, AMPK signaling pathway, Bile secretion D00887 Atorvastatin 18件: 13, 46, 49, 51, 58, 63, 79, 84, 88, 93, 96, 97, 160, 222, 225, 265, 271, 299
404 HMGCR 4件: Terpenoid backbone biosynthesis, Metabolic pathways, AMPK signaling pathway, Bile secretion D00893 Pravastatin 9件: 13, 46, 49, 67, 79, 96, 164, 265, 333
405 HMGCR 4件: Terpenoid backbone biosynthesis, Metabolic pathways, AMPK signaling pathway, Bile secretion D01915 Rosuvastatin 11件: 6, 18, 46, 49, 51, 56, 79, 96, 97, 271, 299
406 HMGCR 4件: Terpenoid backbone biosynthesis, Metabolic pathways, AMPK signaling pathway, Bile secretion D07474 Atorvastatin 18件: 13, 46, 49, 51, 58, 63, 79, 84, 88, 93, 96, 97, 160, 222, 225, 265, 271, 299
407 HMGCR 4件: Terpenoid backbone biosynthesis, Metabolic pathways, AMPK signaling pathway, Bile secretion D08410 Pravastatin 9件: 13, 46, 49, 67, 79, 96, 164, 265, 333
408 HMGCR 4件: Terpenoid backbone biosynthesis, Metabolic pathways, AMPK signaling pathway, Bile secretion D08492 Rosuvastatin 11件: 6, 18, 46, 49, 51, 56, 79, 96, 97, 271, 299
409 HRH1 3件: Calcium signaling pathway, Neuroactive ligand-receptor interaction, Inflammatory mediator regulation of TRP channels D00364 Loratadine 4件: 13, 46, 89, 98
410 HRH1 3件: Calcium signaling pathway, Neuroactive ligand-receptor interaction, Inflammatory mediator regulation of TRP channels D00671 Fexofenadine 2件: 13, 46
411 HRH1 3件: Calcium signaling pathway, Neuroactive ligand-receptor interaction, Inflammatory mediator regulation of TRP channels D07407 Rupatadine 1件: 46
412 HRH1 3件: Calcium signaling pathway, Neuroactive ligand-receptor interaction, Inflammatory mediator regulation of TRP channels D07958 Fexofenadine 2件: 13, 46
413 HRH2 3件: Calcium signaling pathway, Neuroactive ligand-receptor interaction, Gastric acid secretion D00318 Famotidine 7件: 6, 46, 61, 86, 98, 107, 300
414 IFNAR1 18件: Cytokine-cytokine receptor interaction, PI3K-Akt signaling pathway, Necroptosis, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Hepatitis C, Hepatitis B, Measles, Influenza A, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Coronavirus disease - COVID-19, Pathways in cancer D11082 Anifrolumab 2件: 46, 49
415 IFNAR2 17件: Cytokine-cytokine receptor interaction, PI3K-Akt signaling pathway, Necroptosis, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Hepatitis C, Measles, Influenza A, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Coronavirus disease - COVID-19, Pathways in cancer D11082 Anifrolumab 2件: 46, 49
416 IFNG 32件: Proteasome, Cytokine-cytokine receptor interaction, HIF-1 signaling pathway, Necroptosis, TGF-beta signaling pathway, Osteoclast differentiation, Antigen processing and presentation, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, IL-17 signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Type I diabetes mellitus, Leishmaniasis, Chagas disease, African trypanosomiasis, Malaria, Toxoplasmosis, Amoebiasis, Tuberculosis, Hepatitis C, Influenza A, Herpes simplex virus 1 infection, Pathways in cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer, Inflammatory bowel disease, Systemic lupus erythematosus, Rheumatoid arthritis, Allograft rejection, Graft-versus-host disease, Fluid shear stress and atherosclerosis D04242 Fontolizumab 1件: 46
417 IFNG 9件: TGF-beta signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Type I diabetes mellitus, Toxoplasmosis, Tuberculosis, Systemic lupus erythematosus, Rheumatoid arthritis D11120 Emapalumab 2件: 49, 107
418 TUBB8 10件: Phagosome, Gap junction, Alzheimer disease, Parkinson disease, Amyotrophic lateral sclerosis, Huntington disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Salmonella infection D00491 Paclitaxel 2件: 46, 85
419 TUBB8 10件: Phagosome, Gap junction, Alzheimer disease, Parkinson disease, Amyotrophic lateral sclerosis, Huntington disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Salmonella infection D00570 Colchicine 7件: 2, 42, 46, 56, 93, 210, 266
420 TUBB8 10件: Phagosome, Gap junction, Alzheimer disease, Parkinson disease, Amyotrophic lateral sclerosis, Huntington disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Salmonella infection D05333 Paclitaxel 2件: 46, 85
421 TUBB2B 10件: Phagosome, Gap junction, Alzheimer disease, Parkinson disease, Amyotrophic lateral sclerosis, Huntington disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Salmonella infection D00491 Paclitaxel 2件: 46, 85
422 TUBB2B 10件: Phagosome, Gap junction, Alzheimer disease, Parkinson disease, Amyotrophic lateral sclerosis, Huntington disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Salmonella infection D00570 Colchicine 7件: 2, 42, 46, 56, 93, 210, 266
423 TUBB2B 10件: Phagosome, Gap junction, Alzheimer disease, Parkinson disease, Amyotrophic lateral sclerosis, Huntington disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Salmonella infection D05333 Paclitaxel 2件: 46, 85
424 IL1A 21件: MAPK signaling pathway, Cytokine-cytokine receptor interaction, Necroptosis, Cellular senescence, Osteoclast differentiation, Hematopoietic cell lineage, Non-alcoholic fatty liver disease, AGE-RAGE signaling pathway in diabetic complications, Type I diabetes mellitus, Alzheimer disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pertussis, Leishmaniasis, Tuberculosis, Measles, Influenza A, Inflammatory bowel disease, Rheumatoid arthritis, Graft-versus-host disease, Fluid shear stress and atherosclerosis D01583 Pirfenidone 11件: 13, 34, 46, 50, 51, 58, 84, 85, 164, 222, 228
425 IL1A 3件: Type I diabetes mellitus, Tuberculosis, Rheumatoid arthritis D06635 Rilonacept 4件: 51, 106, 107, 266
426 IL1A 3件: Type I diabetes mellitus, Tuberculosis, Rheumatoid arthritis D11253 Bermekimab 1件: 51
427 IL1B 44件: Antifolate resistance, MAPK signaling pathway, Cytokine-cytokine receptor interaction, NF-kappa B signaling pathway, Necroptosis, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, Cytosolic DNA-sensing pathway, C-type lectin receptor signaling pathway, Hematopoietic cell lineage, IL-17 signaling pathway, Th17 cell differentiation, TNF signaling pathway, Inflammatory mediator regulation of TRP channels, Non-alcoholic fatty liver disease, AGE-RAGE signaling pathway in diabetic complications, Alcoholic liver disease, Type I diabetes mellitus, Alzheimer disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Legionellosis, Yersinia infection, Leishmaniasis, Chagas disease, African trypanosomiasis, Malaria, Amoebiasis, Tuberculosis, Measles, Human cytomegalovirus infection, Influenza A, Herpes simplex virus 1 infection, Coronavirus disease - COVID-19, Inflammatory bowel disease, Rheumatoid arthritis, Graft-versus-host disease, Lipid and atherosclerosis, Fluid shear stress and atherosclerosis D01583 Pirfenidone 11件: 13, 34, 46, 50, 51, 58, 84, 85, 164, 222, 228
428 IL1B 9件: Toll-like receptor signaling pathway, Th17 cell differentiation, TNF signaling pathway, Type I diabetes mellitus, Shigellosis, Salmonella infection, Yersinia infection, Tuberculosis, Rheumatoid arthritis D06635 Rilonacept 4件: 51, 106, 107, 266
429 IL1B 44件: Antifolate resistance, MAPK signaling pathway, Cytokine-cytokine receptor interaction, NF-kappa B signaling pathway, Necroptosis, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, Cytosolic DNA-sensing pathway, C-type lectin receptor signaling pathway, Hematopoietic cell lineage, IL-17 signaling pathway, Th17 cell differentiation, TNF signaling pathway, Inflammatory mediator regulation of TRP channels, Non-alcoholic fatty liver disease, AGE-RAGE signaling pathway in diabetic complications, Alcoholic liver disease, Type I diabetes mellitus, Alzheimer disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Legionellosis, Yersinia infection, Leishmaniasis, Chagas disease, African trypanosomiasis, Malaria, Amoebiasis, Tuberculosis, Measles, Human cytomegalovirus infection, Influenza A, Herpes simplex virus 1 infection, Coronavirus disease - COVID-19, Inflammatory bowel disease, Rheumatoid arthritis, Graft-versus-host disease, Lipid and atherosclerosis, Fluid shear stress and atherosclerosis D09315 Canakinumab 10件: 46, 56, 84, 106, 107, 108, 113, 266, 267, 269
430 IL1B 9件: Toll-like receptor signaling pathway, Th17 cell differentiation, TNF signaling pathway, Type I diabetes mellitus, Shigellosis, Salmonella infection, Yersinia infection, Tuberculosis, Rheumatoid arthritis D09911 Gevokizumab 4件: 41, 50, 56, 269
431 IL1R1 13件: MAPK signaling pathway, Cytokine-cytokine receptor interaction, NF-kappa B signaling pathway, Osteoclast differentiation, Hematopoietic cell lineage, Th17 cell differentiation, Inflammatory mediator regulation of TRP channels, Pathogenic Escherichia coli infection, Shigellosis, Amoebiasis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Fluid shear stress and atherosclerosis D02934 Anakinra 19件: 2, 13, 15, 19, 28, 37, 41, 46, 49, 50, 56, 65, 84, 86, 97, 106, 107, 266, 299
432 IL4 16件: Cytokine-cytokine receptor interaction, PI3K-Akt signaling pathway, JAK-STAT signaling pathway, Hematopoietic cell lineage, IL-17 signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Fc epsilon RI signaling pathway, Intestinal immune network for IgA production, Leishmaniasis, Pathways in cancer, Asthma, Autoimmune thyroid disease, Inflammatory bowel disease, Allograft rejection D03117 Binetrakin 1件: 46
433 IL6 51件: EGFR tyrosine kinase inhibitor resistance, Antifolate resistance, Cytokine-cytokine receptor interaction, Viral protein interaction with cytokine and cytokine receptor, HIF-1 signaling pathway, FoxO signaling pathway, PI3K-Akt signaling pathway, Cellular senescence, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, Cytosolic DNA-sensing pathway, C-type lectin receptor signaling pathway, JAK-STAT signaling pathway, Hematopoietic cell lineage, IL-17 signaling pathway, Th17 cell differentiation, TNF signaling pathway, Intestinal immune network for IgA production, Insulin resistance, Non-alcoholic fatty liver disease, AGE-RAGE signaling pathway in diabetic complications, Alcoholic liver disease, Alzheimer disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Salmonella infection, Pertussis, Legionellosis, Yersinia infection, Chagas disease, African trypanosomiasis, Malaria, Amoebiasis, Tuberculosis, Hepatitis B, Measles, Human cytomegalovirus infection, Influenza A, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Coronavirus disease - COVID-19, Pathways in cancer, Transcriptional misregulation in cancer, Inflammatory bowel disease, Rheumatoid arthritis, Graft-versus-host disease, Hypertrophic cardiomyopathy, Lipid and atherosclerosis D01583 Pirfenidone 11件: 13, 34, 46, 50, 51, 58, 84, 85, 164, 222, 228
434 IL6 9件: Viral protein interaction with cytokine and cytokine receptor, Toll-like receptor signaling pathway, Th17 cell differentiation, TNF signaling pathway, Salmonella infection, Yersinia infection, Tuberculosis, Transcriptional misregulation in cancer, Rheumatoid arthritis D08976 Pomalidomide 6件: 28, 34, 51, 85, 227, 331
435 IL6 9件: Viral protein interaction with cytokine and cytokine receptor, Toll-like receptor signaling pathway, Th17 cell differentiation, TNF signaling pathway, Salmonella infection, Yersinia infection, Tuberculosis, Transcriptional misregulation in cancer, Rheumatoid arthritis D09669 Siltuximab 2件: 28, 331
436 IL6 51件: EGFR tyrosine kinase inhibitor resistance, Antifolate resistance, Cytokine-cytokine receptor interaction, Viral protein interaction with cytokine and cytokine receptor, HIF-1 signaling pathway, FoxO signaling pathway, PI3K-Akt signaling pathway, Cellular senescence, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, Cytosolic DNA-sensing pathway, C-type lectin receptor signaling pathway, JAK-STAT signaling pathway, Hematopoietic cell lineage, IL-17 signaling pathway, Th17 cell differentiation, TNF signaling pathway, Intestinal immune network for IgA production, Insulin resistance, Non-alcoholic fatty liver disease, AGE-RAGE signaling pathway in diabetic complications, Alcoholic liver disease, Alzheimer disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Salmonella infection, Pertussis, Legionellosis, Yersinia infection, Chagas disease, African trypanosomiasis, Malaria, Amoebiasis, Tuberculosis, Hepatitis B, Measles, Human cytomegalovirus infection, Influenza A, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Coronavirus disease - COVID-19, Pathways in cancer, Transcriptional misregulation in cancer, Inflammatory bowel disease, Rheumatoid arthritis, Graft-versus-host disease, Hypertrophic cardiomyopathy, Lipid and atherosclerosis D10080 Sirukumab 2件: 41, 46
437 IL6R 12件: EGFR tyrosine kinase inhibitor resistance, Cytokine-cytokine receptor interaction, Viral protein interaction with cytokine and cytokine receptor, HIF-1 signaling pathway, PI3K-Akt signaling pathway, JAK-STAT signaling pathway, Hematopoietic cell lineage, Th17 cell differentiation, Non-alcoholic fatty liver disease, Human cytomegalovirus infection, Coronavirus disease - COVID-19, Pathways in cancer D02596 Tocilizumab 21件: 2, 11, 13, 40, 41, 42, 43, 44, 46, 49, 50, 51, 53, 54, 55, 56, 86, 107, 266, 271, 331
438 IL6R 12件: EGFR tyrosine kinase inhibitor resistance, Cytokine-cytokine receptor interaction, Viral protein interaction with cytokine and cytokine receptor, HIF-1 signaling pathway, PI3K-Akt signaling pathway, JAK-STAT signaling pathway, Hematopoietic cell lineage, Th17 cell differentiation, Non-alcoholic fatty liver disease, Human cytomegalovirus infection, Coronavirus disease - COVID-19, Pathways in cancer D10161 Sarilumab 5件: 41, 46, 84, 107, 271
439 IL10 22件: Cytokine-cytokine receptor interaction, Viral protein interaction with cytokine and cytokine receptor, FoxO signaling pathway, C-type lectin receptor signaling pathway, JAK-STAT signaling pathway, T cell receptor signaling pathway, Intestinal immune network for IgA production, Pertussis, Yersinia infection, Leishmaniasis, Chagas disease, African trypanosomiasis, Malaria, Toxoplasmosis, Amoebiasis, Staphylococcus aureus infection, Tuberculosis, Asthma, Autoimmune thyroid disease, Inflammatory bowel disease, Systemic lupus erythematosus, Allograft rejection D01583 Pirfenidone 11件: 13, 34, 46, 50, 51, 58, 84, 85, 164, 222, 228
440 IL12A 25件: Cytokine-cytokine receptor interaction, Toll-like receptor signaling pathway, RIG-I-like receptor signaling pathway, C-type lectin receptor signaling pathway, JAK-STAT signaling pathway, Th1 and Th2 cell differentiation, Alcoholic liver disease, Type I diabetes mellitus, Pertussis, Legionellosis, Leishmaniasis, Chagas disease, African trypanosomiasis, Malaria, Toxoplasmosis, Amoebiasis, Tuberculosis, Measles, Influenza A, Herpes simplex virus 1 infection, Coronavirus disease - COVID-19, Pathways in cancer, Inflammatory bowel disease, Allograft rejection, Lipid and atherosclerosis D09214 Ustekinumab 17件: 37, 40, 41, 46, 49, 50, 53, 56, 65, 84, 93, 96, 97, 160, 162, 269, 271
441 IL12B 25件: Cytokine-cytokine receptor interaction, Toll-like receptor signaling pathway, RIG-I-like receptor signaling pathway, C-type lectin receptor signaling pathway, JAK-STAT signaling pathway, Th1 and Th2 cell differentiation, Alcoholic liver disease, Type I diabetes mellitus, Pertussis, Legionellosis, Leishmaniasis, Chagas disease, African trypanosomiasis, Toxoplasmosis, Amoebiasis, Tuberculosis, Measles, Influenza A, Herpes simplex virus 1 infection, Coronavirus disease - COVID-19, Pathways in cancer, Proteoglycans in cancer, Inflammatory bowel disease, Allograft rejection, Lipid and atherosclerosis D09214 Ustekinumab 17件: 37, 40, 41, 46, 49, 50, 53, 56, 65, 84, 93, 96, 97, 160, 162, 269, 271
442 IL17A 6件: Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Th17 cell differentiation, Alcoholic liver disease, Inflammatory bowel disease, Rheumatoid arthritis D09967 Secukinumab 8件: 13, 37, 41, 46, 107, 160, 269, 271
443 IL17A 2件: Th17 cell differentiation, Rheumatoid arthritis D10071 Ixekizumab 6件: 36, 37, 107, 162, 269, 271
444 IL17A 2件: Th17 cell differentiation, Rheumatoid arthritis D11127 Tibulizumab 1件: 53
445 IL17A 6件: Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Th17 cell differentiation, Alcoholic liver disease, Inflammatory bowel disease, Rheumatoid arthritis D11550 Bimekizumab 3件: 46, 97, 271
446 IMPDH1 3件: Purine metabolism, Drug metabolism - other enzymes, Metabolic pathways D01392 Mizoribine 8件: 46, 49, 51, 53, 66, 94, 222, 224
447 IMPDH2 3件: Purine metabolism, Drug metabolism - other enzymes, Metabolic pathways D01392 Mizoribine 8件: 46, 49, 51, 53, 66, 94, 222, 224
448 ITGA4 14件: PI3K-Akt signaling pathway, Focal adhesion, ECM-receptor interaction, Cell adhesion molecules, Hematopoietic cell lineage, Leukocyte transendothelial migration, Intestinal immune network for IgA production, Regulation of actin cytoskeleton, Yersinia infection, Leishmaniasis, Human papillomavirus infection, Hypertrophic cardiomyopathy, Arrhythmogenic right ventricular cardiomyopathy, Dilated cardiomyopathy D06886 Natalizumab 6件: 13, 15, 25, 46, 63, 96
449 AR 4件: Oocyte meiosis, Pathways in cancer, Chemical carcinogenesis - receptor activation, Prostate cancer D03338 Calusterone 3件: 2, 46, 71
450 ITGAL 12件: Rap1 signaling pathway, Cell adhesion molecules, Neutrophil extracellular trap formation, Natural killer cell mediated cytotoxicity, Leukocyte transendothelial migration, Regulation of actin cytoskeleton, Malaria, Staphylococcus aureus infection, Human T-cell leukemia virus 1 infection, Epstein-Barr virus infection, Rheumatoid arthritis, Viral myocarditis D03959 Efalizumab 9件: 11, 13, 37, 46, 49, 53, 61, 95, 96
451 JAK1 27件: EGFR tyrosine kinase inhibitor resistance, PI3K-Akt signaling pathway, Necroptosis, Osteoclast differentiation, Signaling pathways regulating pluripotency of stem cells, NOD-like receptor signaling pathway, JAK-STAT signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Leishmaniasis, Toxoplasmosis, Tuberculosis, Hepatitis C, Hepatitis B, Measles, Human cytomegalovirus infection, Influenza A, Human papillomavirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Coronavirus disease - COVID-19, Pathways in cancer, Viral carcinogenesis, Pancreatic cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer D09970 Tofacitinib 15件: 11, 40, 44, 46, 49, 50, 51, 53, 65, 84, 96, 97, 107, 256, 271
452 JAK1 27件: EGFR tyrosine kinase inhibitor resistance, PI3K-Akt signaling pathway, Necroptosis, Osteoclast differentiation, Signaling pathways regulating pluripotency of stem cells, NOD-like receptor signaling pathway, JAK-STAT signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Leishmaniasis, Toxoplasmosis, Tuberculosis, Hepatitis C, Hepatitis B, Measles, Human cytomegalovirus infection, Influenza A, Human papillomavirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Coronavirus disease - COVID-19, Pathways in cancer, Viral carcinogenesis, Pancreatic cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer D10308 Baricitinib 13件: 41, 46, 49, 50, 51, 53, 93, 107, 162, 265, 268, 269, 325
453 JAK1 27件: EGFR tyrosine kinase inhibitor resistance, PI3K-Akt signaling pathway, Necroptosis, Osteoclast differentiation, Signaling pathways regulating pluripotency of stem cells, NOD-like receptor signaling pathway, JAK-STAT signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Leishmaniasis, Toxoplasmosis, Tuberculosis, Hepatitis C, Hepatitis B, Measles, Human cytomegalovirus infection, Influenza A, Human papillomavirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Coronavirus disease - COVID-19, Pathways in cancer, Viral carcinogenesis, Pancreatic cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer D10653 Peficitinib 1件: 46
454 JAK1 27件: EGFR tyrosine kinase inhibitor resistance, PI3K-Akt signaling pathway, Necroptosis, Osteoclast differentiation, Signaling pathways regulating pluripotency of stem cells, NOD-like receptor signaling pathway, JAK-STAT signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Leishmaniasis, Toxoplasmosis, Tuberculosis, Hepatitis C, Hepatitis B, Measles, Human cytomegalovirus infection, Influenza A, Human papillomavirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Coronavirus disease - COVID-19, Pathways in cancer, Viral carcinogenesis, Pancreatic cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer D10871 Filgotinib 6件: 46, 53, 96, 97, 222, 271
455 JAK1 27件: EGFR tyrosine kinase inhibitor resistance, PI3K-Akt signaling pathway, Necroptosis, Osteoclast differentiation, Signaling pathways regulating pluripotency of stem cells, NOD-like receptor signaling pathway, JAK-STAT signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Leishmaniasis, Toxoplasmosis, Tuberculosis, Hepatitis C, Hepatitis B, Measles, Human cytomegalovirus infection, Influenza A, Human papillomavirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Coronavirus disease - COVID-19, Pathways in cancer, Viral carcinogenesis, Pancreatic cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer D10944 Itacitinib 5件: 46, 51, 60, 97, 228
456 JAK1 27件: EGFR tyrosine kinase inhibitor resistance, PI3K-Akt signaling pathway, Necroptosis, Osteoclast differentiation, Signaling pathways regulating pluripotency of stem cells, NOD-like receptor signaling pathway, JAK-STAT signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Leishmaniasis, Toxoplasmosis, Tuberculosis, Hepatitis C, Hepatitis B, Measles, Human cytomegalovirus infection, Influenza A, Human papillomavirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Coronavirus disease - COVID-19, Pathways in cancer, Viral carcinogenesis, Pancreatic cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer D10994 Upadacitinib 8件: 40, 41, 46, 49, 96, 97, 107, 271
457 JAK2 24件: EGFR tyrosine kinase inhibitor resistance, Chemokine signaling pathway, PI3K-Akt signaling pathway, Necroptosis, Signaling pathways regulating pluripotency of stem cells, JAK-STAT signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Cholinergic synapse, Prolactin signaling pathway, Adipocytokine signaling pathway, AGE-RAGE signaling pathway in diabetic complications, Growth hormone synthesis, secretion and action, Leishmaniasis, Toxoplasmosis, Tuberculosis, Hepatitis B, Influenza A, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Pathways in cancer, Chemical carcinogenesis - receptor activation, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis D09970 Tofacitinib 15件: 11, 40, 44, 46, 49, 50, 51, 53, 65, 84, 96, 97, 107, 256, 271
458 JAK2 24件: EGFR tyrosine kinase inhibitor resistance, Chemokine signaling pathway, PI3K-Akt signaling pathway, Necroptosis, Signaling pathways regulating pluripotency of stem cells, JAK-STAT signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Cholinergic synapse, Prolactin signaling pathway, Adipocytokine signaling pathway, AGE-RAGE signaling pathway in diabetic complications, Growth hormone synthesis, secretion and action, Leishmaniasis, Toxoplasmosis, Tuberculosis, Hepatitis B, Influenza A, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Pathways in cancer, Chemical carcinogenesis - receptor activation, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis D10308 Baricitinib 13件: 41, 46, 49, 50, 51, 53, 93, 107, 162, 265, 268, 269, 325
459 JAK2 24件: EGFR tyrosine kinase inhibitor resistance, Chemokine signaling pathway, PI3K-Akt signaling pathway, Necroptosis, Signaling pathways regulating pluripotency of stem cells, JAK-STAT signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Cholinergic synapse, Prolactin signaling pathway, Adipocytokine signaling pathway, AGE-RAGE signaling pathway in diabetic complications, Growth hormone synthesis, secretion and action, Leishmaniasis, Toxoplasmosis, Tuberculosis, Hepatitis B, Influenza A, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Pathways in cancer, Chemical carcinogenesis - receptor activation, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis D10653 Peficitinib 1件: 46
460 JAK3 15件: Chemokine signaling pathway, PI3K-Akt signaling pathway, Necroptosis, Signaling pathways regulating pluripotency of stem cells, JAK-STAT signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Hepatitis B, Measles, Human T-cell leukemia virus 1 infection, Epstein-Barr virus infection, Pathways in cancer, Viral carcinogenesis, Non-small cell lung cancer, Primary immunodeficiency D09970 Tofacitinib 15件: 11, 40, 44, 46, 49, 50, 51, 53, 65, 84, 96, 97, 107, 256, 271
461 JAK3 15件: Chemokine signaling pathway, PI3K-Akt signaling pathway, Necroptosis, Signaling pathways regulating pluripotency of stem cells, JAK-STAT signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Hepatitis B, Measles, Human T-cell leukemia virus 1 infection, Epstein-Barr virus infection, Pathways in cancer, Viral carcinogenesis, Non-small cell lung cancer, Primary immunodeficiency D10653 Peficitinib 1件: 46
462 KIT 11件: MAPK signaling pathway, Ras signaling pathway, Rap1 signaling pathway, Phospholipase D signaling pathway, PI3K-Akt signaling pathway, Hematopoietic cell lineage, Melanogenesis, Pathways in cancer, Acute myeloid leukemia, Breast cancer, Central carbon metabolism in cancer D01441 Imatinib 12件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162
463 KIT 11件: MAPK signaling pathway, Ras signaling pathway, Rap1 signaling pathway, Phospholipase D signaling pathway, PI3K-Akt signaling pathway, Hematopoietic cell lineage, Melanogenesis, Pathways in cancer, Acute myeloid leukemia, Breast cancer, Central carbon metabolism in cancer D08066 Imatinib 12件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162
464 KIT 11件: MAPK signaling pathway, Ras signaling pathway, Rap1 signaling pathway, Phospholipase D signaling pathway, PI3K-Akt signaling pathway, Hematopoietic cell lineage, Melanogenesis, Pathways in cancer, Acute myeloid leukemia, Breast cancer, Central carbon metabolism in cancer D10229 Masitinib 6件: 2, 5, 6, 13, 46, 96
465 LTA 7件: Cytokine-cytokine receptor interaction, Viral protein interaction with cytokine and cytokine receptor, NF-kappa B signaling pathway, TNF signaling pathway, Type I diabetes mellitus, Human T-cell leukemia virus 1 infection, Herpes simplex virus 1 infection D00742 Etanercept 17件: 15, 28, 35, 38, 39, 46, 50, 53, 56, 60, 85, 107, 228, 270, 271, 285, 298
466 LTA 7件: Cytokine-cytokine receptor interaction, Viral protein interaction with cytokine and cytokine receptor, NF-kappa B signaling pathway, TNF signaling pathway, Type I diabetes mellitus, Human T-cell leukemia virus 1 infection, Herpes simplex virus 1 infection D10187 Pateclizumab 1件: 46
467 LTB 3件: Cytokine-cytokine receptor interaction, NF-kappa B signaling pathway, Rheumatoid arthritis D08866 Baminercept 4件: 13, 46, 53, 97
468 MC2R 5件: cAMP signaling pathway, Neuroactive ligand-receptor interaction, Aldosterone synthesis and secretion, Cortisol synthesis and secretion, Cushing syndrome D00146 Corticotropin 15件: 2, 13, 14, 46, 49, 50, 66, 75, 78, 81, 84, 145, 193, 205, 222
469 MMP13 3件: IL-17 signaling pathway, Relaxin signaling pathway, Parathyroid hormone synthesis, secretion and action D08859 Apratastat 1件: 46
470 ACHE 2件: Glycerophospholipid metabolism, Cholinergic synapse D00670 Donepezil 9件: 5, 6, 13, 46, 78, 124, 127, 156, 206
471 ACHE 2件: Glycerophospholipid metabolism, Cholinergic synapse D02068 Tacrine 3件: 46, 271, 299
472 ACHE 2件: Glycerophospholipid metabolism, Cholinergic synapse D07869 Donepezil 9件: 5, 6, 13, 46, 78, 124, 127, 156, 206
473 ACHE 2件: Glycerophospholipid metabolism, Cholinergic synapse D08555 Tacrine 3件: 46, 271, 299
474 MTNR1A 2件: Neuroactive ligand-receptor interaction, Circadian entrainment D02689 Ramelteon 3件: 6, 8, 46
475 MTNR1A 2件: Neuroactive ligand-receptor interaction, Circadian entrainment D08170 Melatonin 12件: 6, 8, 13, 37, 46, 49, 90, 97, 144, 145, 149, 202
476 MTNR1B 2件: Neuroactive ligand-receptor interaction, Circadian entrainment D02689 Ramelteon 3件: 6, 8, 46
477 MTNR1B 2件: Neuroactive ligand-receptor interaction, Circadian entrainment D08170 Melatonin 12件: 6, 8, 13, 37, 46, 49, 90, 97, 144, 145, 149, 202
478 SERPINC1 1件: Complement and coagulation cascades D03674 Enoxaparin 1件: 46
479 SERPINC1 1件: Complement and coagulation cascades D07510 Enoxaparin 1件: 46
480 ATP1A1 18件: cGMP-PKG signaling pathway, cAMP signaling pathway, Cardiac muscle contraction, Adrenergic signaling in cardiomyocytes, Insulin secretion, Thyroid hormone synthesis, Thyroid hormone signaling pathway, Aldosterone synthesis and secretion, Aldosterone-regulated sodium reabsorption, Endocrine and other factor-regulated calcium reabsorption, Proximal tubule bicarbonate reclamation, Salivary secretion, Gastric acid secretion, Pancreatic secretion, Carbohydrate digestion and absorption, Protein digestion and absorption, Bile secretion, Mineral absorption D00298 Digoxin 3件: 8, 46, 210
481 ATP1A2 18件: cGMP-PKG signaling pathway, cAMP signaling pathway, Cardiac muscle contraction, Adrenergic signaling in cardiomyocytes, Insulin secretion, Thyroid hormone synthesis, Thyroid hormone signaling pathway, Aldosterone synthesis and secretion, Aldosterone-regulated sodium reabsorption, Endocrine and other factor-regulated calcium reabsorption, Proximal tubule bicarbonate reclamation, Salivary secretion, Gastric acid secretion, Pancreatic secretion, Carbohydrate digestion and absorption, Protein digestion and absorption, Bile secretion, Mineral absorption D00298 Digoxin 3件: 8, 46, 210
482 ATP1A3 18件: cGMP-PKG signaling pathway, cAMP signaling pathway, Cardiac muscle contraction, Adrenergic signaling in cardiomyocytes, Insulin secretion, Thyroid hormone synthesis, Thyroid hormone signaling pathway, Aldosterone synthesis and secretion, Aldosterone-regulated sodium reabsorption, Endocrine and other factor-regulated calcium reabsorption, Proximal tubule bicarbonate reclamation, Salivary secretion, Gastric acid secretion, Pancreatic secretion, Carbohydrate digestion and absorption, Protein digestion and absorption, Bile secretion, Mineral absorption D00298 Digoxin 3件: 8, 46, 210
483 NFKB1 76件: Antifolate resistance, MAPK signaling pathway, Ras signaling pathway, cAMP signaling pathway, Chemokine signaling pathway, NF-kappa B signaling pathway, HIF-1 signaling pathway, Sphingolipid signaling pathway, PI3K-Akt signaling pathway, Apoptosis, Longevity regulating pathway, Cellular senescence, Osteoclast differentiation, Neutrophil extracellular trap formation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Cytosolic DNA-sensing pathway, C-type lectin receptor signaling pathway, IL-17 signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, B cell receptor signaling pathway, TNF signaling pathway, Neurotrophin signaling pathway, Prolactin signaling pathway, Adipocytokine signaling pathway, Relaxin signaling pathway, Insulin resistance, Non-alcoholic fatty liver disease, AGE-RAGE signaling pathway in diabetic complications, Alcoholic liver disease, Alzheimer disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Epithelial cell signaling in Helicobacter pylori infection, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Legionellosis, Yersinia infection, Leishmaniasis, Chagas disease, Toxoplasmosis, Amoebiasis, Tuberculosis, Hepatitis C, Hepatitis B, Measles, Human cytomegalovirus infection, Influenza A, Human papillomavirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Human immunodeficiency virus 1 infection, Coronavirus disease - COVID-19, Pathways in cancer, Transcriptional misregulation in cancer, Viral carcinogenesis, MicroRNAs in cancer, Chemical carcinogenesis - receptor activation, Chemical carcinogenesis - reactive oxygen species, Pancreatic cancer, Prostate cancer, Chronic myeloid leukemia, Acute myeloid leukemia, Small cell lung cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer, Inflammatory bowel disease, Diabetic cardiomyopathy, Lipid and atherosclerosis, Fluid shear stress and atherosclerosis D01146 Iguratimod 4件: 46, 51, 53, 271
484 ATP1A4 18件: cGMP-PKG signaling pathway, cAMP signaling pathway, Cardiac muscle contraction, Adrenergic signaling in cardiomyocytes, Insulin secretion, Thyroid hormone synthesis, Thyroid hormone signaling pathway, Aldosterone synthesis and secretion, Aldosterone-regulated sodium reabsorption, Endocrine and other factor-regulated calcium reabsorption, Proximal tubule bicarbonate reclamation, Salivary secretion, Gastric acid secretion, Pancreatic secretion, Carbohydrate digestion and absorption, Protein digestion and absorption, Bile secretion, Mineral absorption D00298 Digoxin 3件: 8, 46, 210
485 NPR1 10件: Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway, cAMP signaling pathway, Vascular smooth muscle contraction, Thermogenesis, Oxytocin signaling pathway, Regulation of lipolysis in adipocytes, Renin secretion, Aldosterone synthesis and secretion D04051 Erythrityl tetranitrate 1件: 46
486 NPR1 10件: Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway, cAMP signaling pathway, Vascular smooth muscle contraction, Thermogenesis, Oxytocin signaling pathway, Regulation of lipolysis in adipocytes, Renin secretion, Aldosterone synthesis and secretion D05147 Nesiritide 2件: 46, 58
487 NPR2 5件: Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway, Vascular smooth muscle contraction, Oxytocin signaling pathway D04051 Erythrityl tetranitrate 1件: 46
488 ATP4A 4件: Oxidative phosphorylation, Metabolic pathways, Collecting duct acid secretion, Gastric acid secretion D00455 Omeprazole 16件: 6, 8, 13, 21, 46, 51, 85, 96, 97, 98, 225, 271, 282, 294, 298, 299
489 ATP4A 4件: Oxidative phosphorylation, Metabolic pathways, Collecting duct acid secretion, Gastric acid secretion D01207 Omeprazole 16件: 6, 8, 13, 21, 46, 51, 85, 96, 97, 98, 225, 271, 282, 294, 298, 299
490 ATP4A 4件: Oxidative phosphorylation, Metabolic pathways, Collecting duct acid secretion, Gastric acid secretion D01984 Esomeprazole 8件: 13, 46, 86, 98, 107, 113, 298, 299
491 ATP4A 4件: Oxidative phosphorylation, Metabolic pathways, Collecting duct acid secretion, Gastric acid secretion D04056 Esomeprazole 8件: 13, 46, 86, 98, 107, 113, 298, 299
492 ATP4A 4件: Oxidative phosphorylation, Metabolic pathways, Collecting duct acid secretion, Gastric acid secretion D05259 Omeprazole 16件: 6, 8, 13, 21, 46, 51, 85, 96, 97, 98, 225, 271, 282, 294, 298, 299
493 ATP4A 4件: Oxidative phosphorylation, Metabolic pathways, Collecting duct acid secretion, Gastric acid secretion D05261 Omeprazole 16件: 6, 8, 13, 21, 46, 51, 85, 96, 97, 98, 225, 271, 282, 294, 298, 299
494 ATP4A 4件: Oxidative phosphorylation, Metabolic pathways, Collecting duct acid secretion, Gastric acid secretion D07917 Esomeprazole 8件: 13, 46, 86, 98, 107, 113, 298, 299
495 ATP4A 4件: Oxidative phosphorylation, Metabolic pathways, Collecting duct acid secretion, Gastric acid secretion D09339 Esomeprazole 8件: 13, 46, 86, 98, 107, 113, 298, 299
496 ATP4B 4件: Oxidative phosphorylation, Metabolic pathways, Collecting duct acid secretion, Gastric acid secretion D00455 Omeprazole 16件: 6, 8, 13, 21, 46, 51, 85, 96, 97, 98, 225, 271, 282, 294, 298, 299
497 ATP4B 4件: Oxidative phosphorylation, Metabolic pathways, Collecting duct acid secretion, Gastric acid secretion D01207 Omeprazole 16件: 6, 8, 13, 21, 46, 51, 85, 96, 97, 98, 225, 271, 282, 294, 298, 299
498 ATP4B 4件: Oxidative phosphorylation, Metabolic pathways, Collecting duct acid secretion, Gastric acid secretion D01984 Esomeprazole 8件: 13, 46, 86, 98, 107, 113, 298, 299
499 ATP4B 4件: Oxidative phosphorylation, Metabolic pathways, Collecting duct acid secretion, Gastric acid secretion D04056 Esomeprazole 8件: 13, 46, 86, 98, 107, 113, 298, 299
500 ATP4B 4件: Oxidative phosphorylation, Metabolic pathways, Collecting duct acid secretion, Gastric acid secretion D05259 Omeprazole 16件: 6, 8, 13, 21, 46, 51, 85, 96, 97, 98, 225, 271, 282, 294, 298, 299
501 ATP4B 4件: Oxidative phosphorylation, Metabolic pathways, Collecting duct acid secretion, Gastric acid secretion D05261 Omeprazole 16件: 6, 8, 13, 21, 46, 51, 85, 96, 97, 98, 225, 271, 282, 294, 298, 299
502 ATP4B 4件: Oxidative phosphorylation, Metabolic pathways, Collecting duct acid secretion, Gastric acid secretion D07917 Esomeprazole 8件: 13, 46, 86, 98, 107, 113, 298, 299
503 ATP4B 4件: Oxidative phosphorylation, Metabolic pathways, Collecting duct acid secretion, Gastric acid secretion D09339 Esomeprazole 8件: 13, 46, 86, 98, 107, 113, 298, 299
504 OPRD1 3件: cGMP-PKG signaling pathway, Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction D02095 Naltrexone 13件: 6, 10, 13, 40, 41, 42, 43, 44, 45, 46, 96, 97, 226
505 OPRD1 3件: cGMP-PKG signaling pathway, Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction D03783 Oxycodone 7件: 6, 13, 46, 70, 226, 231, 298
506 OPRD1 3件: cGMP-PKG signaling pathway, Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction D05113 Naltrexone 13件: 6, 10, 13, 40, 41, 42, 43, 44, 45, 46, 96, 97, 226
507 OPRD1 3件: cGMP-PKG signaling pathway, Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction D05312 Oxycodone 7件: 6, 13, 46, 70, 226, 231, 298
508 OPRD1 3件: cGMP-PKG signaling pathway, Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction D05462 Oxycodone 7件: 6, 13, 46, 70, 226, 231, 298
509 OPRK1 1件: Neuroactive ligand-receptor interaction D00836 Buprenorphine 3件: 46, 70, 298
510 OPRK1 1件: Neuroactive ligand-receptor interaction D02095 Naltrexone 4件: 46, 96, 97, 226
511 OPRK1 1件: Neuroactive ligand-receptor interaction D03783 Oxycodone 5件: 46, 70, 226, 231, 298
512 OPRK1 1件: Neuroactive ligand-receptor interaction D05113 Naltrexone 4件: 46, 96, 97, 226
513 OPRK1 1件: Neuroactive ligand-receptor interaction D05312 Oxycodone 5件: 46, 70, 226, 231, 298
514 OPRK1 1件: Neuroactive ligand-receptor interaction D05462 Oxycodone 5件: 46, 70, 226, 231, 298
515 OPRK1 1件: Neuroactive ligand-receptor interaction D07132 Buprenorphine 3件: 46, 70, 298
516 OPRM1 3件: Neuroactive ligand-receptor interaction, Estrogen signaling pathway, Morphine addiction D00320 Fentanyl 4件: 46, 70, 215, 231
517 OPRM1 3件: Neuroactive ligand-receptor interaction, Estrogen signaling pathway, Morphine addiction D00836 Buprenorphine 3件: 46, 70, 298
518 OPRM1 3件: Neuroactive ligand-receptor interaction, Estrogen signaling pathway, Morphine addiction D00842 Morphine 6件: 36, 46, 70, 85, 86, 298
519 OPRM1 3件: Neuroactive ligand-receptor interaction, Estrogen signaling pathway, Morphine addiction D01355 Tramadol 5件: 46, 70, 78, 226, 271
520 OPRM1 3件: Neuroactive ligand-receptor interaction, Estrogen signaling pathway, Morphine addiction D01399 Fentanyl 4件: 46, 70, 215, 231
521 OPRM1 3件: Neuroactive ligand-receptor interaction, Estrogen signaling pathway, Morphine addiction D02095 Naltrexone 13件: 6, 10, 13, 40, 41, 42, 43, 44, 45, 46, 96, 97, 226
522 OPRM1 3件: Neuroactive ligand-receptor interaction, Estrogen signaling pathway, Morphine addiction D02271 Morphine 6件: 36, 46, 70, 85, 86, 298
523 OPRM1 3件: Neuroactive ligand-receptor interaction, Estrogen signaling pathway, Morphine addiction D03783 Oxycodone 7件: 6, 13, 46, 70, 226, 231, 298
524 OPRM1 3件: Neuroactive ligand-receptor interaction, Estrogen signaling pathway, Morphine addiction D05113 Naltrexone 13件: 6, 10, 13, 40, 41, 42, 43, 44, 45, 46, 96, 97, 226
525 OPRM1 3件: Neuroactive ligand-receptor interaction, Estrogen signaling pathway, Morphine addiction D05312 Oxycodone 7件: 6, 13, 46, 70, 226, 231, 298
526 OPRM1 3件: Neuroactive ligand-receptor interaction, Estrogen signaling pathway, Morphine addiction D05462 Oxycodone 7件: 6, 13, 46, 70, 226, 231, 298
527 OPRM1 3件: Neuroactive ligand-receptor interaction, Estrogen signaling pathway, Morphine addiction D07132 Buprenorphine 3件: 46, 70, 298
528 OPRM1 3件: Neuroactive ligand-receptor interaction, Estrogen signaling pathway, Morphine addiction D08233 Morphine 6件: 36, 46, 70, 85, 86, 298
529 OPRM1 3件: Neuroactive ligand-receptor interaction, Estrogen signaling pathway, Morphine addiction D08623 Tramadol 5件: 46, 70, 78, 226, 271
530 IL20 3件: Cytokine-cytokine receptor interaction, Viral protein interaction with cytokine and cytokine receptor, JAK-STAT signaling pathway D11756 Fletikumab 1件: 46
531 PDCD1 3件: Cell adhesion molecules, T cell receptor signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer D10316 Nivolumab 12件: 13, 26, 41, 46, 49, 50, 51, 53, 85, 96, 97, 159
532 PDE2A 6件: Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway, Olfactory transduction, Aldosterone synthesis and secretion, Morphine addiction D00528 Caffeine 9件: 2, 6, 13, 21, 46, 78, 96, 97, 265
533 PDE2A 6件: Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway, Olfactory transduction, Aldosterone synthesis and secretion, Morphine addiction D01453 Caffeine 9件: 2, 6, 13, 21, 46, 78, 96, 97, 265
534 PDE3A 6件: Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway, cAMP signaling pathway, Renin secretion, Morphine addiction D00528 Caffeine 9件: 2, 6, 13, 21, 46, 78, 96, 97, 265
535 PDE3A 6件: Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway, cAMP signaling pathway, Renin secretion, Morphine addiction D01453 Caffeine 9件: 2, 6, 13, 21, 46, 78, 96, 97, 265
536 PDE3B 11件: Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway, cAMP signaling pathway, Apelin signaling pathway, Insulin signaling pathway, Progesterone-mediated oocyte maturation, Glucagon signaling pathway, Regulation of lipolysis in adipocytes, Renin secretion, Morphine addiction D00528 Caffeine 9件: 2, 6, 13, 21, 46, 78, 96, 97, 265
537 PDE3B 11件: Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway, cAMP signaling pathway, Apelin signaling pathway, Insulin signaling pathway, Progesterone-mediated oocyte maturation, Glucagon signaling pathway, Regulation of lipolysis in adipocytes, Renin secretion, Morphine addiction D01453 Caffeine 9件: 2, 6, 13, 21, 46, 78, 96, 97, 265
538 PDE4A 5件: Purine metabolism, Metabolic pathways, cAMP signaling pathway, Parathyroid hormone synthesis, secretion and action, Morphine addiction D00302 Dipyridamole 6件: 46, 49, 51, 66, 96, 224
539 PDE4A 5件: Purine metabolism, Metabolic pathways, cAMP signaling pathway, Parathyroid hormone synthesis, secretion and action, Morphine addiction D00528 Caffeine 9件: 2, 6, 13, 21, 46, 78, 96, 97, 265
540 PDE4A 5件: Purine metabolism, Metabolic pathways, cAMP signaling pathway, Parathyroid hormone synthesis, secretion and action, Morphine addiction D01453 Caffeine 9件: 2, 6, 13, 21, 46, 78, 96, 97, 265
541 PDE4A 5件: Purine metabolism, Metabolic pathways, cAMP signaling pathway, Parathyroid hormone synthesis, secretion and action, Morphine addiction D08860 Apremilast 7件: 46, 50, 56, 97, 107, 162, 271
542 PDE4B 5件: Purine metabolism, Metabolic pathways, cAMP signaling pathway, Parathyroid hormone synthesis, secretion and action, Morphine addiction D00528 Caffeine 9件: 2, 6, 13, 21, 46, 78, 96, 97, 265
543 PDE4B 5件: Purine metabolism, Metabolic pathways, cAMP signaling pathway, Parathyroid hormone synthesis, secretion and action, Morphine addiction D01453 Caffeine 9件: 2, 6, 13, 21, 46, 78, 96, 97, 265
544 PDE4B 5件: Purine metabolism, Metabolic pathways, cAMP signaling pathway, Parathyroid hormone synthesis, secretion and action, Morphine addiction D08860 Apremilast 7件: 46, 50, 56, 97, 107, 162, 271
545 PDE4C 5件: Purine metabolism, Metabolic pathways, cAMP signaling pathway, Parathyroid hormone synthesis, secretion and action, Morphine addiction D00528 Caffeine 9件: 2, 6, 13, 21, 46, 78, 96, 97, 265
546 PDE4C 5件: Purine metabolism, Metabolic pathways, cAMP signaling pathway, Parathyroid hormone synthesis, secretion and action, Morphine addiction D01453 Caffeine 9件: 2, 6, 13, 21, 46, 78, 96, 97, 265
547 PDE4C 5件: Purine metabolism, Metabolic pathways, cAMP signaling pathway, Parathyroid hormone synthesis, secretion and action, Morphine addiction D08860 Apremilast 7件: 46, 50, 56, 97, 107, 162, 271
548 PDE4D 5件: Purine metabolism, Metabolic pathways, cAMP signaling pathway, Parathyroid hormone synthesis, secretion and action, Morphine addiction D00528 Caffeine 9件: 2, 6, 13, 21, 46, 78, 96, 97, 265
549 PDE4D 5件: Purine metabolism, Metabolic pathways, cAMP signaling pathway, Parathyroid hormone synthesis, secretion and action, Morphine addiction D01453 Caffeine 9件: 2, 6, 13, 21, 46, 78, 96, 97, 265
550 PDE4D 5件: Purine metabolism, Metabolic pathways, cAMP signaling pathway, Parathyroid hormone synthesis, secretion and action, Morphine addiction D08860 Apremilast 7件: 46, 50, 56, 97, 107, 162, 271
551 PDE1B 7件: Purine metabolism, Metabolic pathways, Calcium signaling pathway, Olfactory transduction, Taste transduction, Renin secretion, Morphine addiction D00528 Caffeine 9件: 2, 6, 13, 21, 46, 78, 96, 97, 265
552 PDE1B 7件: Purine metabolism, Metabolic pathways, Calcium signaling pathway, Olfactory transduction, Taste transduction, Renin secretion, Morphine addiction D01453 Caffeine 9件: 2, 6, 13, 21, 46, 78, 96, 97, 265
553 IL23A 9件: Cytokine-cytokine receptor interaction, C-type lectin receptor signaling pathway, JAK-STAT signaling pathway, Th17 cell differentiation, Pertussis, Tuberculosis, Pathways in cancer, Inflammatory bowel disease, Rheumatoid arthritis D09214 Ustekinumab 17件: 37, 40, 41, 46, 49, 50, 53, 56, 65, 84, 93, 96, 97, 160, 162, 269, 271
554 IL23A 3件: Th17 cell differentiation, Tuberculosis, Rheumatoid arthritis D10400 Tildrakizumab 2件: 162, 271
555 IL23A 3件: Th17 cell differentiation, Tuberculosis, Rheumatoid arthritis D10438 Guselkumab 5件: 37, 41, 51, 96, 97
556 IL23A 3件: Th17 cell differentiation, Tuberculosis, Rheumatoid arthritis D10912 Brazikumab 2件: 96, 97
557 IL23A 3件: Th17 cell differentiation, Tuberculosis, Rheumatoid arthritis D11052 Risankizumab 4件: 37, 96, 97, 271
558 IL23A 3件: Th17 cell differentiation, Tuberculosis, Rheumatoid arthritis D11123 Mirikizumab 3件: 37, 96, 97
559 PDGFRA 20件: EGFR tyrosine kinase inhibitor resistance, MAPK signaling pathway, Ras signaling pathway, Rap1 signaling pathway, Calcium signaling pathway, Phospholipase D signaling pathway, Endocytosis, PI3K-Akt signaling pathway, Focal adhesion, Gap junction, JAK-STAT signaling pathway, Regulation of actin cytoskeleton, Human cytomegalovirus infection, Pathways in cancer, MicroRNAs in cancer, Glioma, Prostate cancer, Melanoma, Central carbon metabolism in cancer, Choline metabolism in cancer D01441 Imatinib 12件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162
560 PDGFRA 20件: EGFR tyrosine kinase inhibitor resistance, MAPK signaling pathway, Ras signaling pathway, Rap1 signaling pathway, Calcium signaling pathway, Phospholipase D signaling pathway, Endocytosis, PI3K-Akt signaling pathway, Focal adhesion, Gap junction, JAK-STAT signaling pathway, Regulation of actin cytoskeleton, Human cytomegalovirus infection, Pathways in cancer, MicroRNAs in cancer, Glioma, Prostate cancer, Melanoma, Central carbon metabolism in cancer, Choline metabolism in cancer D08066 Imatinib 12件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162
561 PGR 5件: Oocyte meiosis, Progesterone-mediated oocyte maturation, Estrogen signaling pathway, Chemical carcinogenesis - receptor activation, Breast cancer D00182 Norethisterone 4件: 13, 46, 49, 299
562 PGR 5件: Oocyte meiosis, Progesterone-mediated oocyte maturation, Estrogen signaling pathway, Chemical carcinogenesis - receptor activation, Breast cancer D00951 Medroxyprogesterone acetate 6件: 13, 35, 46, 49, 51, 60
563 PGR 5件: Oocyte meiosis, Progesterone-mediated oocyte maturation, Estrogen signaling pathway, Chemical carcinogenesis - receptor activation, Breast cancer D00953 Norethisterone 4件: 13, 46, 49, 299
564 PGR 5件: Oocyte meiosis, Progesterone-mediated oocyte maturation, Estrogen signaling pathway, Chemical carcinogenesis - receptor activation, Breast cancer D08166 Medroxyprogesterone acetate 6件: 13, 35, 46, 49, 51, 60
565 PLG 4件: Neuroactive ligand-receptor interaction, Complement and coagulation cascades, Staphylococcus aureus infection, Influenza A D01136 Tranexamic acid 6件: 46, 70, 215, 227, 288, 299
566 POLA1 1件: DNA replication D03546 Clofarabine 6件: 46, 49, 60, 96, 234, 326
567 PPARG 11件: PPAR signaling pathway, AMPK signaling pathway, Longevity regulating pathway, Osteoclast differentiation, Thermogenesis, Non-alcoholic fatty liver disease, Huntington disease, Pathways in cancer, Transcriptional misregulation in cancer, Thyroid cancer, Lipid and atherosclerosis D00596 Rosiglitazone 5件: 46, 75, 97, 222, 265
568 PPARG 11件: PPAR signaling pathway, AMPK signaling pathway, Longevity regulating pathway, Osteoclast differentiation, Thermogenesis, Non-alcoholic fatty liver disease, Huntington disease, Pathways in cancer, Transcriptional misregulation in cancer, Thyroid cancer, Lipid and atherosclerosis D00945 Pioglitazone 17件: 2, 6, 13, 15, 20, 46, 49, 65, 67, 78, 81, 86, 96, 229, 265, 298, 299
569 PPARG 11件: PPAR signaling pathway, AMPK signaling pathway, Longevity regulating pathway, Osteoclast differentiation, Thermogenesis, Non-alcoholic fatty liver disease, Huntington disease, Pathways in cancer, Transcriptional misregulation in cancer, Thyroid cancer, Lipid and atherosclerosis D08378 Pioglitazone 17件: 2, 6, 13, 15, 20, 46, 49, 65, 67, 78, 81, 86, 96, 229, 265, 298, 299
570 PPARG 11件: PPAR signaling pathway, AMPK signaling pathway, Longevity regulating pathway, Osteoclast differentiation, Thermogenesis, Non-alcoholic fatty liver disease, Huntington disease, Pathways in cancer, Transcriptional misregulation in cancer, Thyroid cancer, Lipid and atherosclerosis D08491 Rosiglitazone 5件: 46, 75, 97, 222, 265
571 PPP3CA 33件: MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, Oocyte meiosis, Cellular senescence, Wnt signaling pathway, Axon guidance, VEGF signaling pathway, Osteoclast differentiation, C-type lectin receptor signaling pathway, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, B cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Oxytocin signaling pathway, Glucagon signaling pathway, Renin secretion, Alzheimer disease, Amyotrophic lateral sclerosis, Prion disease, Pathways of neurodegeneration - multiple diseases, Amphetamine addiction, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis D00107 Tacrolimus 34件: 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299
572 PPP3CA 33件: MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, Oocyte meiosis, Cellular senescence, Wnt signaling pathway, Axon guidance, VEGF signaling pathway, Osteoclast differentiation, C-type lectin receptor signaling pathway, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, B cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Oxytocin signaling pathway, Glucagon signaling pathway, Renin secretion, Alzheimer disease, Amyotrophic lateral sclerosis, Prion disease, Pathways of neurodegeneration - multiple diseases, Amphetamine addiction, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis D00184 Cyclosporine 44件: 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 107, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326
573 PPP3CA 33件: MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, Oocyte meiosis, Cellular senescence, Wnt signaling pathway, Axon guidance, VEGF signaling pathway, Osteoclast differentiation, C-type lectin receptor signaling pathway, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, B cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Oxytocin signaling pathway, Glucagon signaling pathway, Renin secretion, Alzheimer disease, Amyotrophic lateral sclerosis, Prion disease, Pathways of neurodegeneration - multiple diseases, Amphetamine addiction, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis D08556 Tacrolimus 34件: 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299
574 PPP3CB 33件: MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, Oocyte meiosis, Cellular senescence, Wnt signaling pathway, Axon guidance, VEGF signaling pathway, Osteoclast differentiation, C-type lectin receptor signaling pathway, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, B cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Oxytocin signaling pathway, Glucagon signaling pathway, Renin secretion, Alzheimer disease, Amyotrophic lateral sclerosis, Prion disease, Pathways of neurodegeneration - multiple diseases, Amphetamine addiction, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis D00107 Tacrolimus 34件: 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299
575 PPP3CB 33件: MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, Oocyte meiosis, Cellular senescence, Wnt signaling pathway, Axon guidance, VEGF signaling pathway, Osteoclast differentiation, C-type lectin receptor signaling pathway, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, B cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Oxytocin signaling pathway, Glucagon signaling pathway, Renin secretion, Alzheimer disease, Amyotrophic lateral sclerosis, Prion disease, Pathways of neurodegeneration - multiple diseases, Amphetamine addiction, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis D00184 Cyclosporine 44件: 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 107, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326
576 PPP3CB 33件: MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, Oocyte meiosis, Cellular senescence, Wnt signaling pathway, Axon guidance, VEGF signaling pathway, Osteoclast differentiation, C-type lectin receptor signaling pathway, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, B cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Oxytocin signaling pathway, Glucagon signaling pathway, Renin secretion, Alzheimer disease, Amyotrophic lateral sclerosis, Prion disease, Pathways of neurodegeneration - multiple diseases, Amphetamine addiction, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis D08556 Tacrolimus 34件: 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299
577 PPP3CC 33件: MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, Oocyte meiosis, Cellular senescence, Wnt signaling pathway, Axon guidance, VEGF signaling pathway, Osteoclast differentiation, C-type lectin receptor signaling pathway, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, B cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Oxytocin signaling pathway, Glucagon signaling pathway, Renin secretion, Alzheimer disease, Amyotrophic lateral sclerosis, Prion disease, Pathways of neurodegeneration - multiple diseases, Amphetamine addiction, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis D00107 Tacrolimus 34件: 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299
578 PPP3CC 33件: MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, Oocyte meiosis, Cellular senescence, Wnt signaling pathway, Axon guidance, VEGF signaling pathway, Osteoclast differentiation, C-type lectin receptor signaling pathway, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, B cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Oxytocin signaling pathway, Glucagon signaling pathway, Renin secretion, Alzheimer disease, Amyotrophic lateral sclerosis, Prion disease, Pathways of neurodegeneration - multiple diseases, Amphetamine addiction, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis D00184 Cyclosporine 44件: 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 107, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326
579 PPP3CC 33件: MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, Oocyte meiosis, Cellular senescence, Wnt signaling pathway, Axon guidance, VEGF signaling pathway, Osteoclast differentiation, C-type lectin receptor signaling pathway, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, B cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Oxytocin signaling pathway, Glucagon signaling pathway, Renin secretion, Alzheimer disease, Amyotrophic lateral sclerosis, Prion disease, Pathways of neurodegeneration - multiple diseases, Amphetamine addiction, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis D08556 Tacrolimus 34件: 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299
580 PPP3R1 32件: MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, Oocyte meiosis, Cellular senescence, Wnt signaling pathway, Axon guidance, VEGF signaling pathway, Osteoclast differentiation, C-type lectin receptor signaling pathway, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, B cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Oxytocin signaling pathway, Glucagon signaling pathway, Renin secretion, Alzheimer disease, Amyotrophic lateral sclerosis, Prion disease, Pathways of neurodegeneration - multiple diseases, Amphetamine addiction, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis D00107 Tacrolimus 34件: 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299
581 PPP3R1 32件: MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, Oocyte meiosis, Cellular senescence, Wnt signaling pathway, Axon guidance, VEGF signaling pathway, Osteoclast differentiation, C-type lectin receptor signaling pathway, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, B cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Oxytocin signaling pathway, Glucagon signaling pathway, Renin secretion, Alzheimer disease, Amyotrophic lateral sclerosis, Prion disease, Pathways of neurodegeneration - multiple diseases, Amphetamine addiction, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis D00184 Cyclosporine 44件: 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 107, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326
582 PPP3R1 32件: MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, Oocyte meiosis, Cellular senescence, Wnt signaling pathway, Axon guidance, VEGF signaling pathway, Osteoclast differentiation, C-type lectin receptor signaling pathway, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, B cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Oxytocin signaling pathway, Glucagon signaling pathway, Renin secretion, Alzheimer disease, Amyotrophic lateral sclerosis, Prion disease, Pathways of neurodegeneration - multiple diseases, Amphetamine addiction, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis D08556 Tacrolimus 34件: 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299
583 PPP3R2 32件: MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, Oocyte meiosis, Cellular senescence, Wnt signaling pathway, Axon guidance, VEGF signaling pathway, Osteoclast differentiation, C-type lectin receptor signaling pathway, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, B cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Oxytocin signaling pathway, Glucagon signaling pathway, Renin secretion, Alzheimer disease, Amyotrophic lateral sclerosis, Prion disease, Pathways of neurodegeneration - multiple diseases, Amphetamine addiction, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis D00107 Tacrolimus 34件: 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299
584 PPP3R2 32件: MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, Oocyte meiosis, Cellular senescence, Wnt signaling pathway, Axon guidance, VEGF signaling pathway, Osteoclast differentiation, C-type lectin receptor signaling pathway, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, B cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Oxytocin signaling pathway, Glucagon signaling pathway, Renin secretion, Alzheimer disease, Amyotrophic lateral sclerosis, Prion disease, Pathways of neurodegeneration - multiple diseases, Amphetamine addiction, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis D00184 Cyclosporine 44件: 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 107, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326
585 PPP3R2 32件: MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, Oocyte meiosis, Cellular senescence, Wnt signaling pathway, Axon guidance, VEGF signaling pathway, Osteoclast differentiation, C-type lectin receptor signaling pathway, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, B cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Oxytocin signaling pathway, Glucagon signaling pathway, Renin secretion, Alzheimer disease, Amyotrophic lateral sclerosis, Prion disease, Pathways of neurodegeneration - multiple diseases, Amphetamine addiction, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis D08556 Tacrolimus 34件: 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299
586 PRKAA1 20件: FoxO signaling pathway, Autophagy - animal, mTOR signaling pathway, PI3K-Akt signaling pathway, AMPK signaling pathway, Longevity regulating pathway, Longevity regulating pathway - multiple species, Apelin signaling pathway, Tight junction, Circadian rhythm, Thermogenesis, Insulin signaling pathway, Adipocytokine signaling pathway, Oxytocin signaling pathway, Glucagon signaling pathway, Insulin resistance, Non-alcoholic fatty liver disease, Alcoholic liver disease, Hypertrophic cardiomyopathy, Fluid shear stress and atherosclerosis D00944 Metformin 24件: 2, 6, 8, 13, 46, 49, 60, 65, 67, 75, 77, 81, 86, 97, 113, 127, 158, 206, 225, 233, 265, 285, 299, 301
587 PRKAA1 20件: FoxO signaling pathway, Autophagy - animal, mTOR signaling pathway, PI3K-Akt signaling pathway, AMPK signaling pathway, Longevity regulating pathway, Longevity regulating pathway - multiple species, Apelin signaling pathway, Tight junction, Circadian rhythm, Thermogenesis, Insulin signaling pathway, Adipocytokine signaling pathway, Oxytocin signaling pathway, Glucagon signaling pathway, Insulin resistance, Non-alcoholic fatty liver disease, Alcoholic liver disease, Hypertrophic cardiomyopathy, Fluid shear stress and atherosclerosis D04966 Metformin 24件: 2, 6, 8, 13, 46, 49, 60, 65, 67, 75, 77, 81, 86, 97, 113, 127, 158, 206, 225, 233, 265, 285, 299, 301
588 PRKAA2 20件: FoxO signaling pathway, Autophagy - animal, mTOR signaling pathway, PI3K-Akt signaling pathway, AMPK signaling pathway, Longevity regulating pathway, Longevity regulating pathway - multiple species, Apelin signaling pathway, Tight junction, Circadian rhythm, Thermogenesis, Insulin signaling pathway, Adipocytokine signaling pathway, Oxytocin signaling pathway, Glucagon signaling pathway, Insulin resistance, Non-alcoholic fatty liver disease, Alcoholic liver disease, Hypertrophic cardiomyopathy, Fluid shear stress and atherosclerosis D00944 Metformin 24件: 2, 6, 8, 13, 46, 49, 60, 65, 67, 75, 77, 81, 86, 97, 113, 127, 158, 206, 225, 233, 265, 285, 299, 301
589 PRKAA2 20件: FoxO signaling pathway, Autophagy - animal, mTOR signaling pathway, PI3K-Akt signaling pathway, AMPK signaling pathway, Longevity regulating pathway, Longevity regulating pathway - multiple species, Apelin signaling pathway, Tight junction, Circadian rhythm, Thermogenesis, Insulin signaling pathway, Adipocytokine signaling pathway, Oxytocin signaling pathway, Glucagon signaling pathway, Insulin resistance, Non-alcoholic fatty liver disease, Alcoholic liver disease, Hypertrophic cardiomyopathy, Fluid shear stress and atherosclerosis D04966 Metformin 24件: 2, 6, 8, 13, 46, 49, 60, 65, 67, 75, 77, 81, 86, 97, 113, 127, 158, 206, 225, 233, 265, 285, 299, 301
590 CACNA2D3 7件: MAPK signaling pathway, Cardiac muscle contraction, Adrenergic signaling in cardiomyocytes, Oxytocin signaling pathway, Hypertrophic cardiomyopathy, Arrhythmogenic right ventricular cardiomyopathy, Dilated cardiomyopathy D02716 Pregabalin 5件: 13, 36, 46, 70, 298
591 GABRQ 5件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D00267 Chlordiazepoxide 1件: 46
592 GABRQ 5件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D00293 Diazepam 3件: 46, 155, 298
593 GABRQ 5件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D00549 Propofol 10件: 6, 21, 22, 34, 46, 70, 75, 84, 98, 296
594 GABRQ 5件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D00550 Midazolam 12件: 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
595 GABRQ 5件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D00693 Chlordiazepoxide 1件: 46
596 GABRQ 5件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D00696 Midazolam 12件: 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
597 GABRQ 5件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D00706 Zolpidem 3件: 5, 6, 46
598 GABRQ 5件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D01514 Etizolam 1件: 46
599 GABRQ 5件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D02624 Eszopiclone 3件: 6, 13, 46
600 GABRQ 5件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D05028 Midazolam 12件: 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
601 GABRQ 5件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D07784 Delorazepam 3件: 6, 46, 97
602 GABRQ 5件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D08690 Zolpidem 3件: 5, 6, 46
603 PSMB5 8件: Proteasome, Alzheimer disease, Parkinson disease, Amyotrophic lateral sclerosis, Huntington disease, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases D03150 Bortezomib 16件: 11, 13, 26, 28, 46, 49, 51, 61, 63, 64, 66, 228, 256, 283, 288, 331
604 PTAFR 3件: Calcium signaling pathway, Neuroactive ligand-receptor interaction, Staphylococcus aureus infection D07407 Rupatadine 1件: 46
605 PTGER2 6件: cAMP signaling pathway, Neuroactive ligand-receptor interaction, Inflammatory mediator regulation of TRP channels, Renin secretion, Human cytomegalovirus infection, Pathways in cancer D00419 Misoprostol 3件: 46, 70, 271
606 PTGER3 6件: Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Human cytomegalovirus infection, Pathways in cancer D00419 Misoprostol 3件: 46, 70, 271
607 PTGER4 6件: Neuroactive ligand-receptor interaction, Inflammatory mediator regulation of TRP channels, Renin secretion, Human cytomegalovirus infection, Human papillomavirus infection, Pathways in cancer D00419 Misoprostol 3件: 46, 70, 271
608 PTGS1 5件: Arachidonic acid metabolism, Metabolic pathways, Platelet activation, Serotonergic synapse, Regulation of lipolysis in adipocytes D00109 Acetylsalicylic acid 15件: 13, 22, 34, 46, 49, 51, 58, 86, 96, 97, 113, 158, 210, 231, 251
609 PTGS1 5件: Arachidonic acid metabolism, Metabolic pathways, Platelet activation, Serotonergic synapse, Regulation of lipolysis in adipocytes D00118 Naproxen 4件: 13, 46, 107, 271
610 PTGS1 5件: Arachidonic acid metabolism, Metabolic pathways, Platelet activation, Serotonergic synapse, Regulation of lipolysis in adipocytes D00126 Ibuprofen 7件: 13, 46, 65, 107, 113, 271, 299
611 PTGS1 5件: Arachidonic acid metabolism, Metabolic pathways, Platelet activation, Serotonergic synapse, Regulation of lipolysis in adipocytes D00132 Ketoprofen 1件: 46
612 PTGS1 5件: Arachidonic acid metabolism, Metabolic pathways, Platelet activation, Serotonergic synapse, Regulation of lipolysis in adipocytes D00217 Acetaminophen 18件: 3, 6, 11, 13, 34, 35, 46, 49, 51, 70, 86, 96, 222, 231, 256, 271, 300, 337
613 PTGS1 5件: Arachidonic acid metabolism, Metabolic pathways, Platelet activation, Serotonergic synapse, Regulation of lipolysis in adipocytes D00330 Flurbiprofen 3件: 13, 21, 46
614 PTGS1 5件: Arachidonic acid metabolism, Metabolic pathways, Platelet activation, Serotonergic synapse, Regulation of lipolysis in adipocytes D00903 Diclofenac 5件: 13, 34, 46, 78, 271
615 PTGS1 5件: Arachidonic acid metabolism, Metabolic pathways, Platelet activation, Serotonergic synapse, Regulation of lipolysis in adipocytes D00904 Diclofenac 5件: 13, 34, 46, 78, 271
616 PTGS1 5件: Arachidonic acid metabolism, Metabolic pathways, Platelet activation, Serotonergic synapse, Regulation of lipolysis in adipocytes D01122 Ibuprofen 7件: 13, 46, 65, 107, 113, 271, 299
617 PTGS1 5件: Arachidonic acid metabolism, Metabolic pathways, Platelet activation, Serotonergic synapse, Regulation of lipolysis in adipocytes D01475 Flurbiprofen 3件: 13, 21, 46
618 PTGS1 5件: Arachidonic acid metabolism, Metabolic pathways, Platelet activation, Serotonergic synapse, Regulation of lipolysis in adipocytes D01545 Aceclofenac 1件: 46
619 PTGS1 5件: Arachidonic acid metabolism, Metabolic pathways, Platelet activation, Serotonergic synapse, Regulation of lipolysis in adipocytes D02290 Flurbiprofen 3件: 13, 21, 46
620 PTGS1 5件: Arachidonic acid metabolism, Metabolic pathways, Platelet activation, Serotonergic synapse, Regulation of lipolysis in adipocytes D04490 Ibuprofen 7件: 13, 46, 65, 107, 113, 271, 299
621 PTGS1 5件: Arachidonic acid metabolism, Metabolic pathways, Platelet activation, Serotonergic synapse, Regulation of lipolysis in adipocytes D06606 Ibuprofen 7件: 13, 46, 65, 107, 113, 271, 299
622 PTGS1 5件: Arachidonic acid metabolism, Metabolic pathways, Platelet activation, Serotonergic synapse, Regulation of lipolysis in adipocytes D07816 Diclofenac 5件: 13, 34, 46, 78, 271
623 PTGS1 5件: Arachidonic acid metabolism, Metabolic pathways, Platelet activation, Serotonergic synapse, Regulation of lipolysis in adipocytes D08149 Loxoprofen 2件: 46, 271
624 PTGS2 22件: Arachidonic acid metabolism, Metabolic pathways, NF-kappa B signaling pathway, VEGF signaling pathway, C-type lectin receptor signaling pathway, IL-17 signaling pathway, TNF signaling pathway, Retrograde endocannabinoid signaling, Serotonergic synapse, Ovarian steroidogenesis, Oxytocin signaling pathway, Regulation of lipolysis in adipocytes, Alzheimer disease, Pathways of neurodegeneration - multiple diseases, Leishmaniasis, Human cytomegalovirus infection, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer, Chemical carcinogenesis - DNA adducts, MicroRNAs in cancer, Small cell lung cancer D00109 Acetylsalicylic acid 15件: 13, 22, 34, 46, 49, 51, 58, 86, 96, 97, 113, 158, 210, 231, 251
625 PTGS2 22件: Arachidonic acid metabolism, Metabolic pathways, NF-kappa B signaling pathway, VEGF signaling pathway, C-type lectin receptor signaling pathway, IL-17 signaling pathway, TNF signaling pathway, Retrograde endocannabinoid signaling, Serotonergic synapse, Ovarian steroidogenesis, Oxytocin signaling pathway, Regulation of lipolysis in adipocytes, Alzheimer disease, Pathways of neurodegeneration - multiple diseases, Leishmaniasis, Human cytomegalovirus infection, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer, Chemical carcinogenesis - DNA adducts, MicroRNAs in cancer, Small cell lung cancer D00118 Naproxen 4件: 13, 46, 107, 271
626 PTGS2 22件: Arachidonic acid metabolism, Metabolic pathways, NF-kappa B signaling pathway, VEGF signaling pathway, C-type lectin receptor signaling pathway, IL-17 signaling pathway, TNF signaling pathway, Retrograde endocannabinoid signaling, Serotonergic synapse, Ovarian steroidogenesis, Oxytocin signaling pathway, Regulation of lipolysis in adipocytes, Alzheimer disease, Pathways of neurodegeneration - multiple diseases, Leishmaniasis, Human cytomegalovirus infection, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer, Chemical carcinogenesis - DNA adducts, MicroRNAs in cancer, Small cell lung cancer D00126 Ibuprofen 7件: 13, 46, 65, 107, 113, 271, 299
627 PTGS2 22件: Arachidonic acid metabolism, Metabolic pathways, NF-kappa B signaling pathway, VEGF signaling pathway, C-type lectin receptor signaling pathway, IL-17 signaling pathway, TNF signaling pathway, Retrograde endocannabinoid signaling, Serotonergic synapse, Ovarian steroidogenesis, Oxytocin signaling pathway, Regulation of lipolysis in adipocytes, Alzheimer disease, Pathways of neurodegeneration - multiple diseases, Leishmaniasis, Human cytomegalovirus infection, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer, Chemical carcinogenesis - DNA adducts, MicroRNAs in cancer, Small cell lung cancer D00132 Ketoprofen 1件: 46
628 PTGS2 22件: Arachidonic acid metabolism, Metabolic pathways, NF-kappa B signaling pathway, VEGF signaling pathway, C-type lectin receptor signaling pathway, IL-17 signaling pathway, TNF signaling pathway, Retrograde endocannabinoid signaling, Serotonergic synapse, Ovarian steroidogenesis, Oxytocin signaling pathway, Regulation of lipolysis in adipocytes, Alzheimer disease, Pathways of neurodegeneration - multiple diseases, Leishmaniasis, Human cytomegalovirus infection, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer, Chemical carcinogenesis - DNA adducts, MicroRNAs in cancer, Small cell lung cancer D00217 Acetaminophen 18件: 3, 6, 11, 13, 34, 35, 46, 49, 51, 70, 86, 96, 222, 231, 256, 271, 300, 337
629 PTGS2 22件: Arachidonic acid metabolism, Metabolic pathways, NF-kappa B signaling pathway, VEGF signaling pathway, C-type lectin receptor signaling pathway, IL-17 signaling pathway, TNF signaling pathway, Retrograde endocannabinoid signaling, Serotonergic synapse, Ovarian steroidogenesis, Oxytocin signaling pathway, Regulation of lipolysis in adipocytes, Alzheimer disease, Pathways of neurodegeneration - multiple diseases, Leishmaniasis, Human cytomegalovirus infection, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer, Chemical carcinogenesis - DNA adducts, MicroRNAs in cancer, Small cell lung cancer D00315 Etodolac 1件: 46
630 PTGS2 22件: Arachidonic acid metabolism, Metabolic pathways, NF-kappa B signaling pathway, VEGF signaling pathway, C-type lectin receptor signaling pathway, IL-17 signaling pathway, TNF signaling pathway, Retrograde endocannabinoid signaling, Serotonergic synapse, Ovarian steroidogenesis, Oxytocin signaling pathway, Regulation of lipolysis in adipocytes, Alzheimer disease, Pathways of neurodegeneration - multiple diseases, Leishmaniasis, Human cytomegalovirus infection, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer, Chemical carcinogenesis - DNA adducts, MicroRNAs in cancer, Small cell lung cancer D00330 Flurbiprofen 3件: 13, 21, 46
631 PTGS2 22件: Arachidonic acid metabolism, Metabolic pathways, NF-kappa B signaling pathway, VEGF signaling pathway, C-type lectin receptor signaling pathway, IL-17 signaling pathway, TNF signaling pathway, Retrograde endocannabinoid signaling, Serotonergic synapse, Ovarian steroidogenesis, Oxytocin signaling pathway, Regulation of lipolysis in adipocytes, Alzheimer disease, Pathways of neurodegeneration - multiple diseases, Leishmaniasis, Human cytomegalovirus infection, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer, Chemical carcinogenesis - DNA adducts, MicroRNAs in cancer, Small cell lung cancer D00567 Celecoxib 10件: 2, 3, 34, 46, 70, 89, 107, 161, 171, 271
632 PTGS2 22件: Arachidonic acid metabolism, Metabolic pathways, NF-kappa B signaling pathway, VEGF signaling pathway, C-type lectin receptor signaling pathway, IL-17 signaling pathway, TNF signaling pathway, Retrograde endocannabinoid signaling, Serotonergic synapse, Ovarian steroidogenesis, Oxytocin signaling pathway, Regulation of lipolysis in adipocytes, Alzheimer disease, Pathways of neurodegeneration - multiple diseases, Leishmaniasis, Human cytomegalovirus infection, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer, Chemical carcinogenesis - DNA adducts, MicroRNAs in cancer, Small cell lung cancer D00568 Rofecoxib 1件: 46
633 PTGS2 22件: Arachidonic acid metabolism, Metabolic pathways, NF-kappa B signaling pathway, VEGF signaling pathway, C-type lectin receptor signaling pathway, IL-17 signaling pathway, TNF signaling pathway, Retrograde endocannabinoid signaling, Serotonergic synapse, Ovarian steroidogenesis, Oxytocin signaling pathway, Regulation of lipolysis in adipocytes, Alzheimer disease, Pathways of neurodegeneration - multiple diseases, Leishmaniasis, Human cytomegalovirus infection, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer, Chemical carcinogenesis - DNA adducts, MicroRNAs in cancer, Small cell lung cancer D00903 Diclofenac 5件: 13, 34, 46, 78, 271
634 PTGS2 22件: Arachidonic acid metabolism, Metabolic pathways, NF-kappa B signaling pathway, VEGF signaling pathway, C-type lectin receptor signaling pathway, IL-17 signaling pathway, TNF signaling pathway, Retrograde endocannabinoid signaling, Serotonergic synapse, Ovarian steroidogenesis, Oxytocin signaling pathway, Regulation of lipolysis in adipocytes, Alzheimer disease, Pathways of neurodegeneration - multiple diseases, Leishmaniasis, Human cytomegalovirus infection, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer, Chemical carcinogenesis - DNA adducts, MicroRNAs in cancer, Small cell lung cancer D00904 Diclofenac 5件: 13, 34, 46, 78, 271
635 PTGS2 22件: Arachidonic acid metabolism, Metabolic pathways, NF-kappa B signaling pathway, VEGF signaling pathway, C-type lectin receptor signaling pathway, IL-17 signaling pathway, TNF signaling pathway, Retrograde endocannabinoid signaling, Serotonergic synapse, Ovarian steroidogenesis, Oxytocin signaling pathway, Regulation of lipolysis in adipocytes, Alzheimer disease, Pathways of neurodegeneration - multiple diseases, Leishmaniasis, Human cytomegalovirus infection, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer, Chemical carcinogenesis - DNA adducts, MicroRNAs in cancer, Small cell lung cancer D00969 Meloxicam 4件: 46, 49, 271, 296
636 PTGS2 22件: Arachidonic acid metabolism, Metabolic pathways, NF-kappa B signaling pathway, VEGF signaling pathway, C-type lectin receptor signaling pathway, IL-17 signaling pathway, TNF signaling pathway, Retrograde endocannabinoid signaling, Serotonergic synapse, Ovarian steroidogenesis, Oxytocin signaling pathway, Regulation of lipolysis in adipocytes, Alzheimer disease, Pathways of neurodegeneration - multiple diseases, Leishmaniasis, Human cytomegalovirus infection, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer, Chemical carcinogenesis - DNA adducts, MicroRNAs in cancer, Small cell lung cancer D01049 Nimesulide 1件: 46
637 PTGS2 22件: Arachidonic acid metabolism, Metabolic pathways, NF-kappa B signaling pathway, VEGF signaling pathway, C-type lectin receptor signaling pathway, IL-17 signaling pathway, TNF signaling pathway, Retrograde endocannabinoid signaling, Serotonergic synapse, Ovarian steroidogenesis, Oxytocin signaling pathway, Regulation of lipolysis in adipocytes, Alzheimer disease, Pathways of neurodegeneration - multiple diseases, Leishmaniasis, Human cytomegalovirus infection, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer, Chemical carcinogenesis - DNA adducts, MicroRNAs in cancer, Small cell lung cancer D01122 Ibuprofen 7件: 13, 46, 65, 107, 113, 271, 299
638 PTGS2 22件: Arachidonic acid metabolism, Metabolic pathways, NF-kappa B signaling pathway, VEGF signaling pathway, C-type lectin receptor signaling pathway, IL-17 signaling pathway, TNF signaling pathway, Retrograde endocannabinoid signaling, Serotonergic synapse, Ovarian steroidogenesis, Oxytocin signaling pathway, Regulation of lipolysis in adipocytes, Alzheimer disease, Pathways of neurodegeneration - multiple diseases, Leishmaniasis, Human cytomegalovirus infection, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer, Chemical carcinogenesis - DNA adducts, MicroRNAs in cancer, Small cell lung cancer D01475 Flurbiprofen 3件: 13, 21, 46
639 PTGS2 22件: Arachidonic acid metabolism, Metabolic pathways, NF-kappa B signaling pathway, VEGF signaling pathway, C-type lectin receptor signaling pathway, IL-17 signaling pathway, TNF signaling pathway, Retrograde endocannabinoid signaling, Serotonergic synapse, Ovarian steroidogenesis, Oxytocin signaling pathway, Regulation of lipolysis in adipocytes, Alzheimer disease, Pathways of neurodegeneration - multiple diseases, Leishmaniasis, Human cytomegalovirus infection, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer, Chemical carcinogenesis - DNA adducts, MicroRNAs in cancer, Small cell lung cancer D01545 Aceclofenac 1件: 46
640 PTGS2 22件: Arachidonic acid metabolism, Metabolic pathways, NF-kappa B signaling pathway, VEGF signaling pathway, C-type lectin receptor signaling pathway, IL-17 signaling pathway, TNF signaling pathway, Retrograde endocannabinoid signaling, Serotonergic synapse, Ovarian steroidogenesis, Oxytocin signaling pathway, Regulation of lipolysis in adipocytes, Alzheimer disease, Pathways of neurodegeneration - multiple diseases, Leishmaniasis, Human cytomegalovirus infection, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer, Chemical carcinogenesis - DNA adducts, MicroRNAs in cancer, Small cell lung cancer D02290 Flurbiprofen 3件: 13, 21, 46
641 PTGS2 22件: Arachidonic acid metabolism, Metabolic pathways, NF-kappa B signaling pathway, VEGF signaling pathway, C-type lectin receptor signaling pathway, IL-17 signaling pathway, TNF signaling pathway, Retrograde endocannabinoid signaling, Serotonergic synapse, Ovarian steroidogenesis, Oxytocin signaling pathway, Regulation of lipolysis in adipocytes, Alzheimer disease, Pathways of neurodegeneration - multiple diseases, Leishmaniasis, Human cytomegalovirus infection, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer, Chemical carcinogenesis - DNA adducts, MicroRNAs in cancer, Small cell lung cancer D02709 Valdecoxib 1件: 46
642 PTGS2 22件: Arachidonic acid metabolism, Metabolic pathways, NF-kappa B signaling pathway, VEGF signaling pathway, C-type lectin receptor signaling pathway, IL-17 signaling pathway, TNF signaling pathway, Retrograde endocannabinoid signaling, Serotonergic synapse, Ovarian steroidogenesis, Oxytocin signaling pathway, Regulation of lipolysis in adipocytes, Alzheimer disease, Pathways of neurodegeneration - multiple diseases, Leishmaniasis, Human cytomegalovirus infection, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer, Chemical carcinogenesis - DNA adducts, MicroRNAs in cancer, Small cell lung cancer D03710 Etoricoxib 2件: 46, 271
643 PTGS2 22件: Arachidonic acid metabolism, Metabolic pathways, NF-kappa B signaling pathway, VEGF signaling pathway, C-type lectin receptor signaling pathway, IL-17 signaling pathway, TNF signaling pathway, Retrograde endocannabinoid signaling, Serotonergic synapse, Ovarian steroidogenesis, Oxytocin signaling pathway, Regulation of lipolysis in adipocytes, Alzheimer disease, Pathways of neurodegeneration - multiple diseases, Leishmaniasis, Human cytomegalovirus infection, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer, Chemical carcinogenesis - DNA adducts, MicroRNAs in cancer, Small cell lung cancer D03714 Lumiracoxib 1件: 46
644 PTGS2 22件: Arachidonic acid metabolism, Metabolic pathways, NF-kappa B signaling pathway, VEGF signaling pathway, C-type lectin receptor signaling pathway, IL-17 signaling pathway, TNF signaling pathway, Retrograde endocannabinoid signaling, Serotonergic synapse, Ovarian steroidogenesis, Oxytocin signaling pathway, Regulation of lipolysis in adipocytes, Alzheimer disease, Pathways of neurodegeneration - multiple diseases, Leishmaniasis, Human cytomegalovirus infection, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer, Chemical carcinogenesis - DNA adducts, MicroRNAs in cancer, Small cell lung cancer D03716 Parecoxib 2件: 46, 271
645 PTGS2 22件: Arachidonic acid metabolism, Metabolic pathways, NF-kappa B signaling pathway, VEGF signaling pathway, C-type lectin receptor signaling pathway, IL-17 signaling pathway, TNF signaling pathway, Retrograde endocannabinoid signaling, Serotonergic synapse, Ovarian steroidogenesis, Oxytocin signaling pathway, Regulation of lipolysis in adipocytes, Alzheimer disease, Pathways of neurodegeneration - multiple diseases, Leishmaniasis, Human cytomegalovirus infection, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer, Chemical carcinogenesis - DNA adducts, MicroRNAs in cancer, Small cell lung cancer D04490 Ibuprofen 7件: 13, 46, 65, 107, 113, 271, 299
646 PTGS2 22件: Arachidonic acid metabolism, Metabolic pathways, NF-kappa B signaling pathway, VEGF signaling pathway, C-type lectin receptor signaling pathway, IL-17 signaling pathway, TNF signaling pathway, Retrograde endocannabinoid signaling, Serotonergic synapse, Ovarian steroidogenesis, Oxytocin signaling pathway, Regulation of lipolysis in adipocytes, Alzheimer disease, Pathways of neurodegeneration - multiple diseases, Leishmaniasis, Human cytomegalovirus infection, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer, Chemical carcinogenesis - DNA adducts, MicroRNAs in cancer, Small cell lung cancer D06606 Ibuprofen 7件: 13, 46, 65, 107, 113, 271, 299
647 PTGS2 22件: Arachidonic acid metabolism, Metabolic pathways, NF-kappa B signaling pathway, VEGF signaling pathway, C-type lectin receptor signaling pathway, IL-17 signaling pathway, TNF signaling pathway, Retrograde endocannabinoid signaling, Serotonergic synapse, Ovarian steroidogenesis, Oxytocin signaling pathway, Regulation of lipolysis in adipocytes, Alzheimer disease, Pathways of neurodegeneration - multiple diseases, Leishmaniasis, Human cytomegalovirus infection, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer, Chemical carcinogenesis - DNA adducts, MicroRNAs in cancer, Small cell lung cancer D07816 Diclofenac 5件: 13, 34, 46, 78, 271
648 PTGS2 22件: Arachidonic acid metabolism, Metabolic pathways, NF-kappa B signaling pathway, VEGF signaling pathway, C-type lectin receptor signaling pathway, IL-17 signaling pathway, TNF signaling pathway, Retrograde endocannabinoid signaling, Serotonergic synapse, Ovarian steroidogenesis, Oxytocin signaling pathway, Regulation of lipolysis in adipocytes, Alzheimer disease, Pathways of neurodegeneration - multiple diseases, Leishmaniasis, Human cytomegalovirus infection, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer, Chemical carcinogenesis - DNA adducts, MicroRNAs in cancer, Small cell lung cancer D08149 Loxoprofen 2件: 46, 271
649 PTH1R 3件: Neuroactive ligand-receptor interaction, Parathyroid hormone synthesis, secretion and action, Endocrine and other factor-regulated calcium reabsorption D06078 Teriparatide 7件: 46, 65, 68, 70, 71, 235, 274
650 RRM1 5件: Purine metabolism, Pyrimidine metabolism, Glutathione metabolism, Drug metabolism - other enzymes, Metabolic pathways D01907 Fludarabine 19件: 13, 19, 28, 36, 46, 49, 51, 60, 61, 62, 65, 85, 96, 164, 283, 284, 285, 286, 326
651 RRM1 5件: Purine metabolism, Pyrimidine metabolism, Glutathione metabolism, Drug metabolism - other enzymes, Metabolic pathways D03546 Clofarabine 9件: 19, 20, 40, 46, 49, 60, 96, 234, 326
652 RRM1 5件: Purine metabolism, Pyrimidine metabolism, Glutathione metabolism, Drug metabolism - other enzymes, Metabolic pathways D07966 Fludarabine 19件: 13, 19, 28, 36, 46, 49, 51, 60, 61, 62, 65, 85, 96, 164, 283, 284, 285, 286, 326
653 SCN1A 1件: Dopaminergic synapse D00358 Lidocaine 10件: 46, 51, 70, 84, 86, 107, 168, 226, 231, 256
654 SCN1A 1件: Dopaminergic synapse D01287 Levobupivacaine 1件: 46
655 SCN1A 1件: Dopaminergic synapse D01450 Bupivacaine 8件: 46, 51, 53, 70, 96, 168, 226, 298
656 SCN1A 1件: Dopaminergic synapse D02086 Lidocaine 10件: 46, 51, 70, 84, 86, 107, 168, 226, 231, 256
657 SCN1A 1件: Dopaminergic synapse D04048 Ropivacaine 2件: 46, 70
658 SCN1A 1件: Dopaminergic synapse D07552 Bupivacaine 8件: 46, 51, 53, 70, 96, 168, 226, 298
659 SCN1A 1件: Dopaminergic synapse D08116 Levobupivacaine 1件: 46
660 SCN1A 1件: Dopaminergic synapse D08127 Lidocaine 10件: 46, 51, 70, 84, 86, 107, 168, 226, 231, 256
661 SCN1A 1件: Dopaminergic synapse D08490 Ropivacaine 2件: 46, 70
662 SCN2A 1件: Taste transduction D00358 Lidocaine 10件: 46, 51, 70, 84, 86, 107, 168, 226, 231, 256
663 SCN2A 1件: Taste transduction D01287 Levobupivacaine 1件: 46
664 SCN2A 1件: Taste transduction D01450 Bupivacaine 8件: 46, 51, 53, 70, 96, 168, 226, 298
665 SCN2A 1件: Taste transduction D02086 Lidocaine 10件: 46, 51, 70, 84, 86, 107, 168, 226, 231, 256
666 SCN2A 1件: Taste transduction D04048 Ropivacaine 2件: 46, 70
667 SCN2A 1件: Taste transduction D07552 Bupivacaine 8件: 46, 51, 53, 70, 96, 168, 226, 298
668 SCN2A 1件: Taste transduction D08116 Levobupivacaine 1件: 46
669 SCN2A 1件: Taste transduction D08127 Lidocaine 10件: 46, 51, 70, 84, 86, 107, 168, 226, 231, 256
670 SCN2A 1件: Taste transduction D08490 Ropivacaine 2件: 46, 70
671 SCN3A 1件: Taste transduction D00358 Lidocaine 10件: 46, 51, 70, 84, 86, 107, 168, 226, 231, 256
672 SCN3A 1件: Taste transduction D01287 Levobupivacaine 1件: 46
673 SCN3A 1件: Taste transduction D01450 Bupivacaine 8件: 46, 51, 53, 70, 96, 168, 226, 298
674 SCN3A 1件: Taste transduction D02086 Lidocaine 10件: 46, 51, 70, 84, 86, 107, 168, 226, 231, 256
675 SCN3A 1件: Taste transduction D04048 Ropivacaine 2件: 46, 70
676 SCN3A 1件: Taste transduction D07299 Lacosamide 2件: 46, 149
677 SCN3A 1件: Taste transduction D07552 Bupivacaine 8件: 46, 51, 53, 70, 96, 168, 226, 298
678 SCN3A 1件: Taste transduction D08116 Levobupivacaine 1件: 46
679 SCN3A 1件: Taste transduction D08127 Lidocaine 10件: 46, 51, 70, 84, 86, 107, 168, 226, 231, 256
680 SCN3A 1件: Taste transduction D08490 Ropivacaine 2件: 46, 70
681 SCN5A 1件: Adrenergic signaling in cardiomyocytes D00358 Lidocaine 10件: 46, 51, 70, 84, 86, 107, 168, 226, 231, 256
682 SCN5A 1件: Adrenergic signaling in cardiomyocytes D01287 Levobupivacaine 1件: 46
683 SCN5A 1件: Adrenergic signaling in cardiomyocytes D01450 Bupivacaine 8件: 46, 51, 53, 70, 96, 168, 226, 298
684 SCN5A 1件: Adrenergic signaling in cardiomyocytes D02086 Lidocaine 10件: 46, 51, 70, 84, 86, 107, 168, 226, 231, 256
685 SCN5A 1件: Adrenergic signaling in cardiomyocytes D04048 Ropivacaine 2件: 46, 70
686 SCN5A 1件: Adrenergic signaling in cardiomyocytes D07552 Bupivacaine 8件: 46, 51, 53, 70, 96, 168, 226, 298
687 SCN5A 1件: Adrenergic signaling in cardiomyocytes D08116 Levobupivacaine 1件: 46
688 SCN5A 1件: Adrenergic signaling in cardiomyocytes D08127 Lidocaine 10件: 46, 51, 70, 84, 86, 107, 168, 226, 231, 256
689 SCN5A 1件: Adrenergic signaling in cardiomyocytes D08490 Ropivacaine 2件: 46, 70
690 SCN9A 1件: Taste transduction D00358 Lidocaine 10件: 46, 51, 70, 84, 86, 107, 168, 226, 231, 256
691 SCN9A 1件: Taste transduction D01287 Levobupivacaine 1件: 46
692 SCN9A 1件: Taste transduction D01450 Bupivacaine 8件: 46, 51, 53, 70, 96, 168, 226, 298
693 SCN9A 1件: Taste transduction D02086 Lidocaine 10件: 46, 51, 70, 84, 86, 107, 168, 226, 231, 256
694 SCN9A 1件: Taste transduction D04048 Ropivacaine 2件: 46, 70
695 SCN9A 1件: Taste transduction D07299 Lacosamide 2件: 46, 149
696 SCN9A 1件: Taste transduction D07552 Bupivacaine 8件: 46, 51, 53, 70, 96, 168, 226, 298
697 SCN9A 1件: Taste transduction D08116 Levobupivacaine 1件: 46
698 SCN9A 1件: Taste transduction D08127 Lidocaine 10件: 46, 51, 70, 84, 86, 107, 168, 226, 231, 256
699 SCN9A 1件: Taste transduction D08490 Ropivacaine 2件: 46, 70
700 CCL2 17件: Cytokine-cytokine receptor interaction, Viral protein interaction with cytokine and cytokine receptor, Chemokine signaling pathway, NOD-like receptor signaling pathway, IL-17 signaling pathway, TNF signaling pathway, AGE-RAGE signaling pathway in diabetic complications, Yersinia infection, Chagas disease, Malaria, Human cytomegalovirus infection, Influenza A, Herpes simplex virus 1 infection, Coronavirus disease - COVID-19, Rheumatoid arthritis, Lipid and atherosclerosis, Fluid shear stress and atherosclerosis D01583 Pirfenidone 11件: 13, 34, 46, 50, 51, 58, 84, 85, 164, 222, 228
701 P2RY12 1件: Platelet activation D09017 Ticagrelor 2件: 46, 85
702 SLC6A2 1件: Synaptic vesicle cycle D00228 Amoxapine 1件: 46
703 SLC6A2 1件: Synaptic vesicle cycle D00821 Venlafaxine 1件: 46
704 SLC6A2 1件: Synaptic vesicle cycle D08222 Milnacipran 2件: 46, 49
705 SLC6A2 1件: Synaptic vesicle cycle D08670 Venlafaxine 1件: 46
706 SLC6A4 2件: Synaptic vesicle cycle, Serotonergic synapse D00228 Amoxapine 1件: 46
707 SLC6A4 2件: Synaptic vesicle cycle, Serotonergic synapse D00821 Venlafaxine 3件: 6, 13, 46
708 SLC6A4 2件: Synaptic vesicle cycle, Serotonergic synapse D00822 Citalopram 7件: 6, 8, 13, 18, 46, 98, 127
709 SLC6A4 2件: Synaptic vesicle cycle, Serotonergic synapse D02260 Paroxetine 4件: 6, 13, 46, 85
710 SLC6A4 2件: Synaptic vesicle cycle, Serotonergic synapse D02362 Paroxetine 4件: 6, 13, 46, 85
711 SLC6A4 2件: Synaptic vesicle cycle, Serotonergic synapse D05374 Paroxetine 4件: 6, 13, 46, 85
712 SLC6A4 2件: Synaptic vesicle cycle, Serotonergic synapse D05375 Paroxetine 4件: 6, 13, 46, 85
713 SLC6A4 2件: Synaptic vesicle cycle, Serotonergic synapse D07704 Citalopram 7件: 6, 8, 13, 18, 46, 98, 127
714 SLC6A4 2件: Synaptic vesicle cycle, Serotonergic synapse D08222 Milnacipran 2件: 46, 49
715 SLC6A4 2件: Synaptic vesicle cycle, Serotonergic synapse D08670 Venlafaxine 3件: 6, 13, 46
716 SYK 17件: NF-kappa B signaling pathway, Phospholipase D signaling pathway, PI3K-Akt signaling pathway, Osteoclast differentiation, Platelet activation, Neutrophil extracellular trap formation, C-type lectin receptor signaling pathway, Natural killer cell mediated cytotoxicity, B cell receptor signaling pathway, Fc epsilon RI signaling pathway, Fc gamma R-mediated phagocytosis, Tuberculosis, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Coronavirus disease - COVID-19, Viral carcinogenesis D09347 Fostamatinib 4件: 46, 49, 61, 66
717 ADAM17 4件: Notch signaling pathway, Alzheimer disease, Epithelial cell signaling in Helicobacter pylori infection, Coronavirus disease - COVID-19 D08859 Apratastat 1件: 46
718 BTK 7件: NF-kappa B signaling pathway, Osteoclast differentiation, Platelet activation, B cell receptor signaling pathway, Fc epsilon RI signaling pathway, Epstein-Barr virus infection, Primary immunodeficiency D10893 Acalabrutinib 2件: 46, 61
719 BTK 7件: NF-kappa B signaling pathway, Osteoclast differentiation, Platelet activation, B cell receptor signaling pathway, Fc epsilon RI signaling pathway, Epstein-Barr virus infection, Primary immunodeficiency D11478 Branebrutinib 3件: 46, 49, 53
720 TGFB1 5件: TGF-beta signaling pathway, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Rheumatoid arthritis D09620 Fresolimumab 4件: 51, 85, 222, 274
721 TGFB2 4件: TGF-beta signaling pathway, Toxoplasmosis, Tuberculosis, Rheumatoid arthritis D09620 Fresolimumab 4件: 51, 85, 222, 274
722 TGFB3 4件: TGF-beta signaling pathway, Toxoplasmosis, Tuberculosis, Rheumatoid arthritis D09620 Fresolimumab 4件: 51, 85, 222, 274
723 TNF 67件: Antifolate resistance, MAPK signaling pathway, Cytokine-cytokine receptor interaction, Viral protein interaction with cytokine and cytokine receptor, NF-kappa B signaling pathway, Sphingolipid signaling pathway, mTOR signaling pathway, Apoptosis, Necroptosis, TGF-beta signaling pathway, Osteoclast differentiation, Antigen processing and presentation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, C-type lectin receptor signaling pathway, Hematopoietic cell lineage, Natural killer cell mediated cytotoxicity, IL-17 signaling pathway, T cell receptor signaling pathway, Fc epsilon RI signaling pathway, TNF signaling pathway, Adipocytokine signaling pathway, Type II diabetes mellitus, Insulin resistance, Non-alcoholic fatty liver disease, AGE-RAGE signaling pathway in diabetic complications, Alcoholic liver disease, Type I diabetes mellitus, Alzheimer disease, Amyotrophic lateral sclerosis, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Legionellosis, Yersinia infection, Leishmaniasis, Chagas disease, African trypanosomiasis, Malaria, Toxoplasmosis, Amoebiasis, Tuberculosis, Hepatitis C, Hepatitis B, Human cytomegalovirus infection, Influenza A, Human papillomavirus infection, Human T-cell leukemia virus 1 infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Human immunodeficiency virus 1 infection, Coronavirus disease - COVID-19, Proteoglycans in cancer, Asthma, Inflammatory bowel disease, Systemic lupus erythematosus, Rheumatoid arthritis, Allograft rejection, Graft-versus-host disease, Hypertrophic cardiomyopathy, Dilated cardiomyopathy, Lipid and atherosclerosis, Fluid shear stress and atherosclerosis D00742 Etanercept 17件: 15, 28, 35, 38, 39, 46, 50, 53, 56, 60, 85, 107, 228, 270, 271, 285, 298
724 TNF 16件: Viral protein interaction with cytokine and cytokine receptor, Sphingolipid signaling pathway, TGF-beta signaling pathway, Toll-like receptor signaling pathway, RIG-I-like receptor signaling pathway, T cell receptor signaling pathway, TNF signaling pathway, Type II diabetes mellitus, Type I diabetes mellitus, Shigellosis, Salmonella infection, Yersinia infection, Toxoplasmosis, Tuberculosis, Systemic lupus erythematosus, Rheumatoid arthritis D00754 Thalidomide 20件: 2, 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331
725 TNF 67件: Antifolate resistance, MAPK signaling pathway, Cytokine-cytokine receptor interaction, Viral protein interaction with cytokine and cytokine receptor, NF-kappa B signaling pathway, Sphingolipid signaling pathway, mTOR signaling pathway, Apoptosis, Necroptosis, TGF-beta signaling pathway, Osteoclast differentiation, Antigen processing and presentation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, C-type lectin receptor signaling pathway, Hematopoietic cell lineage, Natural killer cell mediated cytotoxicity, IL-17 signaling pathway, T cell receptor signaling pathway, Fc epsilon RI signaling pathway, TNF signaling pathway, Adipocytokine signaling pathway, Type II diabetes mellitus, Insulin resistance, Non-alcoholic fatty liver disease, AGE-RAGE signaling pathway in diabetic complications, Alcoholic liver disease, Type I diabetes mellitus, Alzheimer disease, Amyotrophic lateral sclerosis, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Legionellosis, Yersinia infection, Leishmaniasis, Chagas disease, African trypanosomiasis, Malaria, Toxoplasmosis, Amoebiasis, Tuberculosis, Hepatitis C, Hepatitis B, Human cytomegalovirus infection, Influenza A, Human papillomavirus infection, Human T-cell leukemia virus 1 infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Human immunodeficiency virus 1 infection, Coronavirus disease - COVID-19, Proteoglycans in cancer, Asthma, Inflammatory bowel disease, Systemic lupus erythematosus, Rheumatoid arthritis, Allograft rejection, Graft-versus-host disease, Hypertrophic cardiomyopathy, Dilated cardiomyopathy, Lipid and atherosclerosis, Fluid shear stress and atherosclerosis D01583 Pirfenidone 11件: 13, 34, 46, 50, 51, 58, 84, 85, 164, 222, 228
726 TNF 67件: Antifolate resistance, MAPK signaling pathway, Cytokine-cytokine receptor interaction, Viral protein interaction with cytokine and cytokine receptor, NF-kappa B signaling pathway, Sphingolipid signaling pathway, mTOR signaling pathway, Apoptosis, Necroptosis, TGF-beta signaling pathway, Osteoclast differentiation, Antigen processing and presentation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, C-type lectin receptor signaling pathway, Hematopoietic cell lineage, Natural killer cell mediated cytotoxicity, IL-17 signaling pathway, T cell receptor signaling pathway, Fc epsilon RI signaling pathway, TNF signaling pathway, Adipocytokine signaling pathway, Type II diabetes mellitus, Insulin resistance, Non-alcoholic fatty liver disease, AGE-RAGE signaling pathway in diabetic complications, Alcoholic liver disease, Type I diabetes mellitus, Alzheimer disease, Amyotrophic lateral sclerosis, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Legionellosis, Yersinia infection, Leishmaniasis, Chagas disease, African trypanosomiasis, Malaria, Toxoplasmosis, Amoebiasis, Tuberculosis, Hepatitis C, Hepatitis B, Human cytomegalovirus infection, Influenza A, Human papillomavirus infection, Human T-cell leukemia virus 1 infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Human immunodeficiency virus 1 infection, Coronavirus disease - COVID-19, Proteoglycans in cancer, Asthma, Inflammatory bowel disease, Systemic lupus erythematosus, Rheumatoid arthritis, Allograft rejection, Graft-versus-host disease, Hypertrophic cardiomyopathy, Dilated cardiomyopathy, Lipid and atherosclerosis, Fluid shear stress and atherosclerosis D02597 Adalimumab 18件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 151, 160, 164, 222, 226, 269, 270, 271
727 TNF 67件: Antifolate resistance, MAPK signaling pathway, Cytokine-cytokine receptor interaction, Viral protein interaction with cytokine and cytokine receptor, NF-kappa B signaling pathway, Sphingolipid signaling pathway, mTOR signaling pathway, Apoptosis, Necroptosis, TGF-beta signaling pathway, Osteoclast differentiation, Antigen processing and presentation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, C-type lectin receptor signaling pathway, Hematopoietic cell lineage, Natural killer cell mediated cytotoxicity, IL-17 signaling pathway, T cell receptor signaling pathway, Fc epsilon RI signaling pathway, TNF signaling pathway, Adipocytokine signaling pathway, Type II diabetes mellitus, Insulin resistance, Non-alcoholic fatty liver disease, AGE-RAGE signaling pathway in diabetic complications, Alcoholic liver disease, Type I diabetes mellitus, Alzheimer disease, Amyotrophic lateral sclerosis, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Legionellosis, Yersinia infection, Leishmaniasis, Chagas disease, African trypanosomiasis, Malaria, Toxoplasmosis, Amoebiasis, Tuberculosis, Hepatitis C, Hepatitis B, Human cytomegalovirus infection, Influenza A, Human papillomavirus infection, Human T-cell leukemia virus 1 infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Human immunodeficiency virus 1 infection, Coronavirus disease - COVID-19, Proteoglycans in cancer, Asthma, Inflammatory bowel disease, Systemic lupus erythematosus, Rheumatoid arthritis, Allograft rejection, Graft-versus-host disease, Hypertrophic cardiomyopathy, Dilated cardiomyopathy, Lipid and atherosclerosis, Fluid shear stress and atherosclerosis D02598 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271
728 TNF 67件: Antifolate resistance, MAPK signaling pathway, Cytokine-cytokine receptor interaction, Viral protein interaction with cytokine and cytokine receptor, NF-kappa B signaling pathway, Sphingolipid signaling pathway, mTOR signaling pathway, Apoptosis, Necroptosis, TGF-beta signaling pathway, Osteoclast differentiation, Antigen processing and presentation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, C-type lectin receptor signaling pathway, Hematopoietic cell lineage, Natural killer cell mediated cytotoxicity, IL-17 signaling pathway, T cell receptor signaling pathway, Fc epsilon RI signaling pathway, TNF signaling pathway, Adipocytokine signaling pathway, Type II diabetes mellitus, Insulin resistance, Non-alcoholic fatty liver disease, AGE-RAGE signaling pathway in diabetic complications, Alcoholic liver disease, Type I diabetes mellitus, Alzheimer disease, Amyotrophic lateral sclerosis, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Legionellosis, Yersinia infection, Leishmaniasis, Chagas disease, African trypanosomiasis, Malaria, Toxoplasmosis, Amoebiasis, Tuberculosis, Hepatitis C, Hepatitis B, Human cytomegalovirus infection, Influenza A, Human papillomavirus infection, Human T-cell leukemia virus 1 infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Human immunodeficiency virus 1 infection, Coronavirus disease - COVID-19, Proteoglycans in cancer, Asthma, Inflammatory bowel disease, Systemic lupus erythematosus, Rheumatoid arthritis, Allograft rejection, Graft-versus-host disease, Hypertrophic cardiomyopathy, Dilated cardiomyopathy, Lipid and atherosclerosis, Fluid shear stress and atherosclerosis D03441 Certolizumab pegol 8件: 37, 46, 49, 96, 97, 107, 226, 271
729 TNF 67件: Antifolate resistance, MAPK signaling pathway, Cytokine-cytokine receptor interaction, Viral protein interaction with cytokine and cytokine receptor, NF-kappa B signaling pathway, Sphingolipid signaling pathway, mTOR signaling pathway, Apoptosis, Necroptosis, TGF-beta signaling pathway, Osteoclast differentiation, Antigen processing and presentation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, C-type lectin receptor signaling pathway, Hematopoietic cell lineage, Natural killer cell mediated cytotoxicity, IL-17 signaling pathway, T cell receptor signaling pathway, Fc epsilon RI signaling pathway, TNF signaling pathway, Adipocytokine signaling pathway, Type II diabetes mellitus, Insulin resistance, Non-alcoholic fatty liver disease, AGE-RAGE signaling pathway in diabetic complications, Alcoholic liver disease, Type I diabetes mellitus, Alzheimer disease, Amyotrophic lateral sclerosis, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Legionellosis, Yersinia infection, Leishmaniasis, Chagas disease, African trypanosomiasis, Malaria, Toxoplasmosis, Amoebiasis, Tuberculosis, Hepatitis C, Hepatitis B, Human cytomegalovirus infection, Influenza A, Human papillomavirus infection, Human T-cell leukemia virus 1 infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Human immunodeficiency virus 1 infection, Coronavirus disease - COVID-19, Proteoglycans in cancer, Asthma, Inflammatory bowel disease, Systemic lupus erythematosus, Rheumatoid arthritis, Allograft rejection, Graft-versus-host disease, Hypertrophic cardiomyopathy, Dilated cardiomyopathy, Lipid and atherosclerosis, Fluid shear stress and atherosclerosis D04358 Golimumab 8件: 46, 56, 84, 96, 97, 107, 270, 271
730 TNF 16件: Viral protein interaction with cytokine and cytokine receptor, Sphingolipid signaling pathway, TGF-beta signaling pathway, Toll-like receptor signaling pathway, RIG-I-like receptor signaling pathway, T cell receptor signaling pathway, TNF signaling pathway, Type II diabetes mellitus, Type I diabetes mellitus, Shigellosis, Salmonella infection, Yersinia infection, Toxoplasmosis, Tuberculosis, Systemic lupus erythematosus, Rheumatoid arthritis D04687 Lenalidomide 8件: 16, 26, 28, 34, 49, 284, 300, 331
731 TNF 67件: Antifolate resistance, MAPK signaling pathway, Cytokine-cytokine receptor interaction, Viral protein interaction with cytokine and cytokine receptor, NF-kappa B signaling pathway, Sphingolipid signaling pathway, mTOR signaling pathway, Apoptosis, Necroptosis, TGF-beta signaling pathway, Osteoclast differentiation, Antigen processing and presentation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, C-type lectin receptor signaling pathway, Hematopoietic cell lineage, Natural killer cell mediated cytotoxicity, IL-17 signaling pathway, T cell receptor signaling pathway, Fc epsilon RI signaling pathway, TNF signaling pathway, Adipocytokine signaling pathway, Type II diabetes mellitus, Insulin resistance, Non-alcoholic fatty liver disease, AGE-RAGE signaling pathway in diabetic complications, Alcoholic liver disease, Type I diabetes mellitus, Alzheimer disease, Amyotrophic lateral sclerosis, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Legionellosis, Yersinia infection, Leishmaniasis, Chagas disease, African trypanosomiasis, Malaria, Toxoplasmosis, Amoebiasis, Tuberculosis, Hepatitis C, Hepatitis B, Human cytomegalovirus infection, Influenza A, Human papillomavirus infection, Human T-cell leukemia virus 1 infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Human immunodeficiency virus 1 infection, Coronavirus disease - COVID-19, Proteoglycans in cancer, Asthma, Inflammatory bowel disease, Systemic lupus erythematosus, Rheumatoid arthritis, Allograft rejection, Graft-versus-host disease, Hypertrophic cardiomyopathy, Dilated cardiomyopathy, Lipid and atherosclerosis, Fluid shear stress and atherosclerosis D05393 Pegsunercept 1件: 46
732 TNF 16件: Viral protein interaction with cytokine and cytokine receptor, Sphingolipid signaling pathway, TGF-beta signaling pathway, Toll-like receptor signaling pathway, RIG-I-like receptor signaling pathway, T cell receptor signaling pathway, TNF signaling pathway, Type II diabetes mellitus, Type I diabetes mellitus, Shigellosis, Salmonella infection, Yersinia infection, Toxoplasmosis, Tuberculosis, Systemic lupus erythematosus, Rheumatoid arthritis D08976 Pomalidomide 6件: 28, 34, 51, 85, 227, 331
733 TNF 67件: Antifolate resistance, MAPK signaling pathway, Cytokine-cytokine receptor interaction, Viral protein interaction with cytokine and cytokine receptor, NF-kappa B signaling pathway, Sphingolipid signaling pathway, mTOR signaling pathway, Apoptosis, Necroptosis, TGF-beta signaling pathway, Osteoclast differentiation, Antigen processing and presentation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, C-type lectin receptor signaling pathway, Hematopoietic cell lineage, Natural killer cell mediated cytotoxicity, IL-17 signaling pathway, T cell receptor signaling pathway, Fc epsilon RI signaling pathway, TNF signaling pathway, Adipocytokine signaling pathway, Type II diabetes mellitus, Insulin resistance, Non-alcoholic fatty liver disease, AGE-RAGE signaling pathway in diabetic complications, Alcoholic liver disease, Type I diabetes mellitus, Alzheimer disease, Amyotrophic lateral sclerosis, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Legionellosis, Yersinia infection, Leishmaniasis, Chagas disease, African trypanosomiasis, Malaria, Toxoplasmosis, Amoebiasis, Tuberculosis, Hepatitis C, Hepatitis B, Human cytomegalovirus infection, Influenza A, Human papillomavirus infection, Human T-cell leukemia virus 1 infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Human immunodeficiency virus 1 infection, Coronavirus disease - COVID-19, Proteoglycans in cancer, Asthma, Inflammatory bowel disease, Systemic lupus erythematosus, Rheumatoid arthritis, Allograft rejection, Graft-versus-host disease, Hypertrophic cardiomyopathy, Dilated cardiomyopathy, Lipid and atherosclerosis, Fluid shear stress and atherosclerosis D09944 Ozoralizumab 1件: 46
734 TUBB2A 10件: Phagosome, Gap junction, Alzheimer disease, Parkinson disease, Amyotrophic lateral sclerosis, Huntington disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Salmonella infection D00491 Paclitaxel 2件: 46, 85
735 TUBB2A 10件: Phagosome, Gap junction, Alzheimer disease, Parkinson disease, Amyotrophic lateral sclerosis, Huntington disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Salmonella infection D00570 Colchicine 7件: 2, 42, 46, 56, 93, 210, 266
736 TUBB2A 10件: Phagosome, Gap junction, Alzheimer disease, Parkinson disease, Amyotrophic lateral sclerosis, Huntington disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Salmonella infection D05333 Paclitaxel 2件: 46, 85
737 TYK2 16件: Necroptosis, Osteoclast differentiation, NOD-like receptor signaling pathway, JAK-STAT signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Hepatitis C, Hepatitis B, Measles, Influenza A, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Coronavirus disease - COVID-19 D09970 Tofacitinib 15件: 11, 40, 44, 46, 49, 50, 51, 53, 65, 84, 96, 97, 107, 256, 271
738 TYMS 4件: Pyrimidine metabolism, One carbon pool by folate, Metabolic pathways, Antifolate resistance D01244 Tegafur 1件: 46
739 VDR 5件: Parathyroid hormone synthesis, secretion and action, Endocrine and other factor-regulated calcium reabsorption, Mineral absorption, Tuberculosis, Chemical carcinogenesis - receptor activation D00129 Calcitriol 9件: 18, 37, 46, 49, 66, 96, 158, 235, 326
740 VDR 5件: Parathyroid hormone synthesis, secretion and action, Endocrine and other factor-regulated calcium reabsorption, Mineral absorption, Tuberculosis, Chemical carcinogenesis - receptor activation D00187 Ergocalciferol 6件: 46, 49, 84, 96, 97, 299
741 VDR 5件: Parathyroid hormone synthesis, secretion and action, Endocrine and other factor-regulated calcium reabsorption, Mineral absorption, Tuberculosis, Chemical carcinogenesis - receptor activation D00188 Cholecalciferol 25件: 6, 13, 19, 20, 28, 34, 46, 49, 51, 53, 56, 60, 65, 75, 84, 85, 96, 97, 98, 162, 202, 228, 271, 298, 299
742 VDR 5件: Parathyroid hormone synthesis, secretion and action, Endocrine and other factor-regulated calcium reabsorption, Mineral absorption, Tuberculosis, Chemical carcinogenesis - receptor activation D01518 Alfacalcidol 8件: 41, 46, 49, 50, 96, 107, 235, 238
743 VDR 5件: Parathyroid hormone synthesis, secretion and action, Endocrine and other factor-regulated calcium reabsorption, Mineral absorption, Tuberculosis, Chemical carcinogenesis - receptor activation D07578 Eldecalcitol 1件: 46
744 VEGFA 2件: VEGF signaling pathway, Rheumatoid arthritis D05697 Ranibizumab 4件: 34, 166, 227, 301
745 VEGFA 2件: VEGF signaling pathway, Rheumatoid arthritis D06409 Bevacizumab 9件: 13, 34, 85, 86, 87, 89, 227, 280, 331
746 VEGFA 2件: VEGF signaling pathway, Rheumatoid arthritis D09574 Aflibercept 2件: 90, 166
747 XDH 5件: Purine metabolism, Caffeine metabolism, Drug metabolism - other enzymes, Metabolic pathways, Peroxisome D00224 Allopurinol 6件: 6, 46, 57, 66, 96, 97
748 CACNA2D1 7件: MAPK signaling pathway, Cardiac muscle contraction, Adrenergic signaling in cardiomyocytes, Oxytocin signaling pathway, Hypertrophic cardiomyopathy, Arrhythmogenic right ventricular cardiomyopathy, Dilated cardiomyopathy D02716 Pregabalin 5件: 13, 36, 46, 70, 298
749 IL1R2 7件: Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, Amoebiasis, Human T-cell leukemia virus 1 infection, Transcriptional misregulation in cancer, Prostate cancer, Fluid shear stress and atherosclerosis D02934 Anakinra 19件: 2, 13, 15, 19, 28, 37, 41, 46, 49, 50, 56, 65, 84, 86, 97, 106, 107, 266, 299
750 VKORC1 3件: Ubiquinone and other terpenoid-quinone biosynthesis, Metabolic pathways, Biosynthesis of cofactors D00564 Warfarin 13件: 6, 8, 13, 19, 46, 49, 66, 85, 86, 88, 91, 96, 97
751 VKORC1 3件: Ubiquinone and other terpenoid-quinone biosynthesis, Metabolic pathways, Biosynthesis of cofactors D01280 Warfarin 13件: 6, 8, 13, 19, 46, 49, 66, 85, 86, 88, 91, 96, 97
752 VKORC1 3件: Ubiquinone and other terpenoid-quinone biosynthesis, Metabolic pathways, Biosynthesis of cofactors D08682 Warfarin 13件: 6, 8, 13, 19, 46, 49, 66, 85, 86, 88, 91, 96, 97
753 TUBB1 10件: Phagosome, Gap junction, Alzheimer disease, Parkinson disease, Amyotrophic lateral sclerosis, Huntington disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Salmonella infection D00491 Paclitaxel 2件: 46, 85
754 TUBB1 10件: Phagosome, Gap junction, Alzheimer disease, Parkinson disease, Amyotrophic lateral sclerosis, Huntington disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Salmonella infection D00570 Colchicine 7件: 2, 42, 46, 56, 93, 210, 266
755 TUBB1 10件: Phagosome, Gap junction, Alzheimer disease, Parkinson disease, Amyotrophic lateral sclerosis, Huntington disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Salmonella infection D05333 Paclitaxel 2件: 46, 85
756 TUBB6 10件: Phagosome, Gap junction, Alzheimer disease, Parkinson disease, Amyotrophic lateral sclerosis, Huntington disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Salmonella infection D00491 Paclitaxel 2件: 46, 85
757 TUBB6 10件: Phagosome, Gap junction, Alzheimer disease, Parkinson disease, Amyotrophic lateral sclerosis, Huntington disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Salmonella infection D00570 Colchicine 7件: 2, 42, 46, 56, 93, 210, 266
758 TUBB6 10件: Phagosome, Gap junction, Alzheimer disease, Parkinson disease, Amyotrophic lateral sclerosis, Huntington disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Salmonella infection D05333 Paclitaxel 2件: 46, 85
759 TNFSF11 8件: Cytokine-cytokine receptor interaction, NF-kappa B signaling pathway, Osteoclast differentiation, Prolactin signaling pathway, Parathyroid hormone synthesis, secretion and action, Chemical carcinogenesis - receptor activation, Breast cancer, Rheumatoid arthritis D03684 Denosumab 7件: 46, 50, 93, 95, 96, 274, 299
760 PDE5A 3件: Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway D00302 Dipyridamole 6件: 46, 49, 51, 66, 96, 224
761 PDE5A 3件: Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway D00528 Caffeine 9件: 2, 6, 13, 21, 46, 78, 96, 97, 265
762 PDE5A 3件: Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway D01453 Caffeine 9件: 2, 6, 13, 21, 46, 78, 96, 97, 265
763 PDE5A 3件: Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway D02229 Sildenafil 17件: 6, 46, 50, 51, 85, 86, 90, 113, 210, 211, 212, 225, 226, 278, 294, 299, 301
764 PDE5A 3件: Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway D08514 Sildenafil 17件: 6, 46, 50, 51, 85, 86, 90, 113, 210, 211, 212, 225, 226, 278, 294, 299, 301
765 TNFSF13 3件: Cytokine-cytokine receptor interaction, Intestinal immune network for IgA production, Rheumatoid arthritis D09704 Atacicept 4件: 13, 46, 49, 66
766 CD3D 11件: Hematopoietic cell lineage, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Chagas disease, Measles, Human T-cell leukemia virus 1 infection, Epstein-Barr virus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Primary immunodeficiency D08959 Otelixizumab 1件: 46
767 CD3E 11件: Hematopoietic cell lineage, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Chagas disease, Measles, Human T-cell leukemia virus 1 infection, Epstein-Barr virus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Primary immunodeficiency D08959 Otelixizumab 1件: 46
768 CD3G 10件: Hematopoietic cell lineage, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Chagas disease, Measles, Human T-cell leukemia virus 1 infection, Epstein-Barr virus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer D08959 Otelixizumab 1件: 46
769 CACNA2D2 7件: MAPK signaling pathway, Cardiac muscle contraction, Adrenergic signaling in cardiomyocytes, Oxytocin signaling pathway, Hypertrophic cardiomyopathy, Arrhythmogenic right ventricular cardiomyopathy, Dilated cardiomyopathy D02716 Pregabalin 5件: 13, 36, 46, 70, 298
770 MS4A1 1件: Hematopoietic cell lineage D02994 Rituximab 36件: 46, 49, 50, 51, 52, 53, 55, 56, 60, 61, 63, 64, 65, 66, 83, 84, 85, 86, 93, 94, 96, 97, 127, 162, 222, 229, 256, 271, 274, 283, 284, 285, 288, 296, 300, 331
771 MS4A1 1件: Hematopoietic cell lineage D05218 Ocrelizumab 2件: 46, 49
772 MS4A1 1件: Hematopoietic cell lineage D09031 Veltuzumab 1件: 46
773 MS4A1 1件: Hematopoietic cell lineage D09314 Ofatumumab 1件: 46
774 CACNA2D4 7件: MAPK signaling pathway, Cardiac muscle contraction, Adrenergic signaling in cardiomyocytes, Oxytocin signaling pathway, Hypertrophic cardiomyopathy, Arrhythmogenic right ventricular cardiomyopathy, Dilated cardiomyopathy D02716 Pregabalin 5件: 13, 36, 46, 70, 298
775 CD80 10件: Cell adhesion molecules, Toll-like receptor signaling pathway, Intestinal immune network for IgA production, Type I diabetes mellitus, Autoimmune thyroid disease, Systemic lupus erythematosus, Rheumatoid arthritis, Allograft rejection, Graft-versus-host disease, Viral myocarditis D03203 Abatacept 26件: 11, 13, 19, 41, 44, 46, 49, 50, 51, 53, 55, 60, 65, 84, 93, 95, 96, 97, 107, 160, 164, 222, 271, 284, 285, 300
776 CD80 10件: Cell adhesion molecules, Toll-like receptor signaling pathway, Intestinal immune network for IgA production, Type I diabetes mellitus, Autoimmune thyroid disease, Systemic lupus erythematosus, Rheumatoid arthritis, Allograft rejection, Graft-versus-host disease, Viral myocarditis D03222 Belatacept 1件: 46
777 CD86 12件: Cell adhesion molecules, Toll-like receptor signaling pathway, Intestinal immune network for IgA production, Type I diabetes mellitus, Kaposi sarcoma-associated herpesvirus infection, Transcriptional misregulation in cancer, Autoimmune thyroid disease, Systemic lupus erythematosus, Rheumatoid arthritis, Allograft rejection, Graft-versus-host disease, Viral myocarditis D03203 Abatacept 26件: 11, 13, 19, 41, 44, 46, 49, 50, 51, 53, 55, 60, 65, 84, 93, 95, 96, 97, 107, 160, 164, 222, 271, 284, 285, 300
778 CD86 12件: Cell adhesion molecules, Toll-like receptor signaling pathway, Intestinal immune network for IgA production, Type I diabetes mellitus, Kaposi sarcoma-associated herpesvirus infection, Transcriptional misregulation in cancer, Autoimmune thyroid disease, Systemic lupus erythematosus, Rheumatoid arthritis, Allograft rejection, Graft-versus-host disease, Viral myocarditis D03222 Belatacept 1件: 46
779 PTGES 2件: Arachidonic acid metabolism, Metabolic pathways D01545 Aceclofenac 1件: 46
780 NR1H4 1件: Bile secretion D00734 Ursodeoxycholic acid 11件: 46, 67, 84, 93, 94, 95, 96, 97, 234, 296, 299